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I. INTRODUCTION 
Cancer remains the second leading cause of death worldwide with almost 
1/6th of deaths being related to cancer [1]. In 2012, the WHO recorded 14.1 
million of new diagnoses and 8.2 million of cancer related deaths [2]. Among 
men, lung cancer is globally the most commonly diagnosed form and most 
common cause of cancer death, whereas in women, breast cancer occurs 
most frequently [3]. About every third case is attributed to an unhealthy 
lifestyle which includes obesity, lack of physical activity and excessive 
consumption of alcohol or tobacco. The latter has emerged a major risk 
factor being responsible for 22% of cancer deaths [1].  
Cancer arises when healthy cells degenerate and transform into malignant 
tumor cells. The underlying cause encompasses genetic predisposition and 
external parameters like physical, chemical or biological factors, but also 
dietary habits or chronic infections like hepatitis B and C or human 
papillomavirus (HPV) [1]. Another important aspect is ageing: A drastic 
ascent in the incidence can be found with an increase of age. This finding 
can be explained by an accumulation of risk factors, but also by the fact that 
the cells’ repair mechanisms become less effective over time [1]. Consistent 
with this tendency, Germany experienced a rise of cancer cases between 
2002 and 2012 that ranged around 13% in men and 10% in women, which 
is traced back to the demographic change with a growing proportion of older 
people [4]. 
In terms of therapeutic outcome and prognosis, the time of diagnosis is 
essential. Various forms of cancer like breast cancer or cervical cancer 
show promising cure rates when diagnosed at an early stage [1]. Certainly, 
each type of cancer requires a specific treatment protocol. Most established 
treatment methods include surgery, radiation and chemotherapy. However, 
once the primary tumor has started to metastasize to distant sites of the 
body, surgery becomes inconvenient. Another major weakness is the 
growing development of chemoresistance that hampers success rates of 
chemotherapy. Considering these drawbacks that conventional methods 
are confronted with, the need for innovative treatment options becomes 
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crucial. Therefore, this thesis deals with the establishment of efficient carrier 
systems for the delivery of small interfering RNA (siRNA) and introduces a 
novel drug combination as alternative to conventional treatment regimens. 
1. Nucleic acid therapy using siRNA 
Nucleic acid therapeutics are gaining more and more attention in the 
treatment of several diseases. There are two main groups with opposite 
effects to be distinguished: On the one hand, messenger RNA (mRNA) and 
plasmid DNA (pDNA) promote the expression of a gene product [5], thus 
enhance a gene function, while antisense oligonucleotides and siRNA on 
the other hand, lead to a knockdown of the target gene product [6], thus 
hamper a gene function. 
siRNA, as a non-coding RNA, interferes directly with the expression of a 
gene product by specifically downregulating the target mRNA, and therefore 
represents a promising therapeutic tool in combatting various diseases [7-
11]. It consists of two strands, one guide strand (antisense strand) and one 
passenger strand (sense strand) with 21 to 23 nucleotides. Once it has 
reached the cytosol of its target cell, the two strands are cleaved and the 
guide strand is incorporated into the RNA induced silencing complex 
(RISC), while the passenger strand is degraded. Through the incorporation 
of siRNA, RISC gets enabled to detect the target mRNA, which will 
subsequently be cleaved by the activated RNase part of the complex 
(referred to as argonaute protein 2, or Ago2). Finally, this degradation 
results in a knockdown of the disease-associated gene product (Figure 1) 
[6, 12, 13]. 
To the present day, several siRNA-based therapeutics have entered clinical 
trials [14]. In August 2018, the US FDA approved Patisiran (OnpattroTM, a 
PEGylated liposomal transthyretin (TTR) siRNA formulation) as first siRNA 
drug for the treatment of hereditary transthyretin-mediated amyloidosis 
(hATTR) [15]. However, siRNA therapeutics in general are repeatedly 
confronted with drawbacks regarding their tolerability [14, 16], so more effort 
has to be made in designing stable and efficient, nevertheless 
biocompatible carrier systems. 
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Figure 1: Gene silencing mediated by siRNA. After reaching the 
cytoplasm, double-stranded siRNA is cleaved. The passenger (=sense) 
strand is degraded, while the guide (=antisense) strand is incorporated into 
the RISC complex. This leads to an activation of Ago 2, the RNase part of 
the complex. The matching mRNA sequence can be identified and 
subsequently cleaved resulting in a knockdown of the disease-associated 
gene product. 
 
1.1. Obstacles in siRNA delivery 
Despite very encouraging advances in siRNA research and the great 
potential of this attractive tool in the therapy of various diseases, siRNA 
delivery faces some major drawbacks. Naked siRNA presents very poor 
pharmacokinetic properties and gets cleared from the circulation already a 
few minutes after intravenous injection [17]. In fact, siRNA is confronted with 
several hurdles after systemic application that an ideal carrier should 
overcome. First, siRNA containing nanoparticles have to prevent their 
content from recognition by macrophages and other immune cells. Also, 
degradation by serum nucleases can pose a threat. Therefore, an optimal 
delivery system should shield siRNA from unwanted interactions with blood 
components and by that prolong its circulation time [18]. Another biological 
barrier is the fast renal clearance of particles of a certain size. This problem 
can be solved by creating nanoparticles that range from 10 to 200 nm, as 
renal clearance occurs for particles smaller than 10 nm [19], while sizes 
larger than 200 nm favor degradation by macrophages of the 
reticulo-endothelial system (RES) [20, 21]. Extravasation in the tumor area 
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is facilitated, as tumor vasculature of many solid tumors is leaky, exhibiting 
higher permeability than vessels of normal tissue [22]. Once a particle 
extravasates, it has to pass the extracellular matrix to finally reach its target 
cell. Upon entry into the cell by endocytosis, which is the preferred 
mechanism of most carrier systems [23], the siRNA particle has to escape 
the endosome to reach its final destination, the cytosol (Figure 2). Since 
endosomes exhibit an increasingly acidic pH, endosomal escape should 
happen early after internalization.  
 
 
Figure 2: Mechanism of siRNA delivery. After intravenous administration 
of siRNA polyplexes, particles extravasate in the tumor tissue, since blood 
vessels in this area are extremely leaky. Polyplexes travel through the 
extracellular matrix and by endocytosis enter the tumor cell. As the 
endosome gets increasingly acidic, endosomal escape is mediated by the 
polyplex to release siRNA to the cytoplasm, where it is incorporated into the 
RISC complex.  
 
1.2. Carrier systems for siRNA and drug delivery 
To deliver siRNA to its site of action and overcome the aforementioned 
biological barriers, carriers require certain properties. Above all, in order to 
prevent systemic side effects, they should be both biocompatible and 
biodegradable [24]. Moreover, they should not provoke immune responses, 
hence be nonimmunogenic. siRNA should be protected from degradation 
by serum nucleases and distribution after systemic application should 
certainly reach the target tissue. Ultimately, endosomal escape should be 
effectively triggered after entering the cell [25, 26]. 
When it comes to carrier systems, two major groups can be distinguished: 
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Viral vectors and non-viral vectors. On the one hand, viral vectors display 
an excellent transfection efficiency, which is attributed to the ability of 
viruses to efficiently infect host cells. Although in most cases, the coding 
regions responsible for replication and toxicity are removed from the virus 
genome, viral vectors still bear various risks like their immunogenicity, 
infectious and oncogenic potential [27]. Also, they present very limited 
loading capacity and their synthesis in high quantities remains challenging 
[28, 29]. On the other hand, non-viral vectors present very promising 
alternatives to viruses for the delivery of nucleic acids. As most encouraging 
carriers of this group, cationic polymers and liposomes have emerged [30]. 
As the nucleic acid backbone is negatively charged, electrostatic 
interactions with polymers and liposomes lead to the formation of stable 
particles, then referred to as polyplex or lipoplex [31]. This process also 
implies a condensation of the nucleic acid, enabling the internalization into 
the target cell via endocytosis [32]. Among the polycations, linear 
polyethylenimine (LPEI) became the gold standard in gene delivery [33]. 
After endocytosis, in order to deliver their cargo to the cytosol, endosomal 
release is achieved by the polycations’ proton-sponge properties, hence 
osmotic swelling is induced, followed by rupture of the endosome [34]. 
However, these nanoparticles are confronted with immunogenicity and 
degradation by the RES. Moreover, they exhibit poor biodegradability [35], 
and their cationic charge and molecular weight often provoke unwanted side 
effects. In order to improve efficiency and increase tolerability, various 
functional domains can be introduced into these carrier systems and by that 
mediate surface shielding, active targeting or endosomal escape [36]. 
Anyway, carriers are not only exploited for nucleic acid delivery. Also, 
regarding in vivo drug delivery, carrier systems provide various advantages 
as compared to the administration of free drugs. Firstly, they prolong 
circulation times of small molecule drugs due to their optimized size and 
surface modifications [37, 38]. Secondly, coming along with the increased 
size as well as surface shielding, passive targeting is enabled [39]. Thirdly, 
ligands for active targeting might be introduced to the nanoparticle to 
facilitate cellular uptake. Ultimately, several drugs with different 
pharmacokinetic properties can be encapsulated and thereby delivered 
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simultaneously to the target site [40]. 
1.2.1. Precise sequence-defined oligomers 
Our group has been working on the development of new cationic carrier 
systems. By solid-phase supported synthesis, we have been creating 
sequence-defined oligoaminoamides and until today designed more than 
1200 oligomers with different functional moieties and various modifications 
for efficient nucleic acid or drug delivery. These oligomers are small, 
peptide-like structures with proton-sponge properties [34]. In contrast to 
conventional polymers, our oligomers are smaller in size while their cationic 
character is diminished. The combination of both aspects results in a 
reduced cytotoxicity. 
Hartmann et al. were the first to design precise, sequence-defined 
oligomers [41]. Subsequently, these novel carrier systems were further 
refined by Schaffert et al. and Dohmen et al. who introduced more building 
blocks into the carrier systems [42] and included additional substructures 
into the polymeric backbone [43]. 
Primarily, an oligomer consists of a linear backbone, which is made from 
two artificial amino acids: Succinoyl-pentaethylene-hexamine (Sph) and 
succinoyl-tetraethylene-pentamine (Stp) serving as building blocks. These 
amino acids are responsible for polyplex formation, as they are positively 
charged due to their partly protonated state in neutral pH. siRNA however, 
is negatively charged, hence polymer and nucleic acid can form a polyplex 
with advantageous properties for siRNA delivery [44]. Further modifications 
can be introduced into the oligomer. Cysteines are often used as they are 
able to form disulfide bonds and thereby increase stability. Modification with 
histidines leads to improved endosomal buffering capacity, whereas 
tyrosines and fatty acids mediate stabilization through their hydrophobic 
properties. Various topological subclasses can be distinguished, for 
example linear, 2-arm, 3-arm, 4-arm or T-shaped oligomers. Topology has 
a major impact on nucleic acid complexation and polyplex characteristics 
[45-47]. Regarding siRNA delivery, for example, T-shape oligomers proved 
to be most suitable. They are characterized by the modification of the 
cationic backbone with a hydrophobic domain, typically consisting in two 
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fatty acid units. As aforementioned, fatty acids enhance the polyplex’s 
stability, which is of great importance in the extracellular space. After 
internalization into the target cell, however, hydrophobic domains and 
siRNA binding backbone have to disassemble to release siRNA to the 
cytosol [47, 48]. Disassembly can be facilitated by the introduction of 
disulfide building blocks (ssbb), which can be located between both 
domains. ssbb units represent bio-reducible bonds. Hence, siRNA binding 
polycationic backbone and fatty acid units get cleaved upon entry into the 
cytosol and siRNA is released for incorporation into the RISC [49]. 
Another important aspect is the polymer’s surface shielding, on the one 
hand preventing undesired interactions with blood components and on the 
other hand prolonging circulation time, which finally leads to improved 
passive targeting by the enhanced permeability and retention (EPR) effect 
[50]. Ultimately, to direct the polyplex to the desired region and facilitate 
cellular uptake, active targeting can be provided by introducing a targeting 
ligand to the polyplex.  
1.3. Surface shielding of nanoparticles 
To prevent nanoparticles from quick elimination through renal clearance and 
unspecific interactions with blood components or other nanoparticles, 
shielding agents can be attached to a particle’s surface [50-52]. By 
protecting the particle from degradation, shielding agents significantly 
prolong its circulation time in the bloodstream, hence passive targeting 
through EPR is improved [53, 54]. 
Up until now, the most widely used shielding agent is polyethylene glycol 
(PEG). Klibanov et al. first demonstrated in 1990 the prolonged circulation 
time that was achieved by introducing PEG [50]. As uncharged, hydrophilic 
polymer, it builds a hydrated shell around the nanoparticle, sterically 
protecting it from undesired interactions [55]. However, more and more 
reports declare immune responses to PEG, in the worst case leading to a 
rapid clearance of the so-shielded nanoparticles from circulation [55-61]. 
One such example was published by Abu Lila et al. who demonstrated the 
production of IgM antibodies against PEG in animals that were injected with 
PEG repeatedly [62]. Given the mounting evidence that PEG in some 
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formulations may cause immune responses, the search for alternative 
shielding agents becomes interesting. Several shielding agents are 
currently being evaluated, for example natural proteins [63], 
oligosaccharides [64, 65], hydroxyethyl starch (HES) [66], 
proline-alanine-serine motif (PAS) [67, 68], hydroxypropylmethacrylamide 
(HPMA) [65], or poly(2-isoxazoline) [69]. Yet, none of the aforementioned 
fulfills all criteria collected in the Whiteside’s rules for protein resistant 
surfaces. According to these guidelines, an optimal shielding agent should 
be a non-charged, hydrophilic polymer that exhibits hydrogen acceptor 
properties but lacks hydrogen bond donor groups [70]. Polysarcosine (PSar) 
emerged as one possible alternative to PEG. It belongs to the class of 
polypeptoides, polymers with a structural resemblance to polypeptides [71], 
and exhibits all of the advantageous characteristics. Its resistance to 
proteins was demonstrated on several surfaces [72-74]. Moreover, 
prolonged circulation times could be shown in vivo [75, 76], while in various 
animal models, no immunogenicity or complement activation was reported 
[77]. Also, in human serum, aggregation could be prevented successfully 
[78-81]. Taken together, PSar appears a suitable option for nanoparticle 
shielding in vivo.  
1.4. Active and passive targeting of nanoparticles 
In order to direct a nanoparticle to its site of action, a formulation can be 
modified in various ways. The goal of reaching the target tissue can be 
achieved by either enabling passive targeting or introducing a ligand for 
active targeting. 
Passive targeting exploits the enhanced permeability and retention (EPR) 
effect, which was first described by Matsumara and Maeda in 1986 [22]. 
This effect is based on various aspects. The nanoparticle’s size and 
circulation time and two characteristics of tumoral tissue: Its leaky blood 
vessels and the lack of effective lymphatic drainage. Ideally, 
macromolecules should have a size in the nanometer range to evade renal 
filtration [19]. Also, to take advantage of the EPR effect, they should remain 
not less than 6 h within the blood circulation [82]. This can be accomplished 
by surface shielding, providing effective protection against opsonization and 
fast renal clearance [53, 54], which would otherwise occur rapidly after 
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systemic application [83]. In normal tissues, endothelial cells are separated 
by tight junctions which only allow small molecules of 2 to 4 nm to pass, 
whereas they are impermeable for larger nanoparticles. Inside the tumor 
tissue, however, vessels exhibit a different morphology, which is attributed 
to the fast tumor growth accompanied by extensive angiogenesis to keep 
up the supply with oxygen and nutrients. In contrast to normal blood vessels, 
tumor vessels exhibit gap junctions and pores. Due to this “leakiness”, 
macromolecules up to a size of 600 nm are able to penetrate the 
endothelium and extravasate to the tumor tissue [84]. In addition, the 
lymphatic drainage of tumors is only poorly developed, so removal of 
nanoparticles from the tumor is impeded [85, 86].  
Active targeting, on the other side, promotes attachment at the target tissue 
and cellular internalization of the formulation through receptor-specific 
uptake. Unlike most cells of normal tissues, many tumor cell lines 
overexpress certain surface receptors, which can consequently be targeted 
by suitable targeting ligands incorporated into the nanoparticle. Some 
examples for commonly targeted receptors are folate receptor (FR) [87-94], 
epidermal growth factor receptor (EGFR) [95-98] or transferrin receptor 
(TfR) [99-101]. These receptors can be addressed by various groups of 
targeting ligands which can be introduced into the nanoparticle. Some of the 
most commonly used classes are small molecules [102], peptides [103, 
104], glycoproteins [105] or antibodies [106, 107]. 
In this thesis, the focus lies on the FR and the EGFR targeted delivery. FR 
is overexpressed in many epithelial tumors [87, 94], while in normal tissues 
its expression rate is rather low [93, 108]. This can be explained by the high 
division rate of tumor cells: Folic acid (FolA), the main ligand of the FR, is 
an essential vitamin. After entering the cell via the FR or the reduced folate 
carrier (RFC), it is transferred to dihydrofolate and tetrahydrofolate by the 
enzyme dihydrofolate reductase (DHFR). In this active form, it is required 
for the de novo synthesis of DNA and RNA [109, 110]. Likewise, receptor 
tyrosine kinase EGFR is overexpressed in many solid tumors [111]. Its 
expression is associated with poor prognosis [112, 113]. Using the natural 
ligand epidermal growth factor (EGF) bears a mitogenic risk due to an 
activation of EGFR, which can successfully be evaded by using GE11 
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peptide as alternative targeting ligand [114].  
 
2. Combination chemotherapy as therapeutic approach 
Besides radiation and surgery, chemotherapy remains the most important 
pillar in cancer therapy. However, the efficiency of chemotherapy is 
frequently hampered due to the development of resistances when 
treatments are administered in a monotherapy approach [115, 116]. There 
are numerous mechanisms of resistance formation, including DNA damage 
repair [117, 118], drug inactivation [119] and cell death inhibition [120]. 
Currently, the best option to reduce this risk, is the combination of two or 
more therapeutic agents [121-123]. By co-administering various 
compounds with different mechanisms of action, multiple targets can be 
addressed and by achieving a synergistic or additive effect, therapeutic 
efficacy can be increased at lower doses of either drug [124, 125].  
Already in 1965, Frei et al. reported the successful administration of a 
combination therapy regimen to pediatric patients suffering from acute 
lymphocytic leukemia. This approach, formally referred to as POMP 
regimen led to long-term remission by combining 6-mercaptopurine, 
vincristine, prednisone and methotrexate (MTX) [126, 127].  
However, it is essential to contemplate the pharmacodynamic interactions 
that occur when multiple drugs are combined [128]. As aforementioned, 
drugs can enhance each other’s efficiency in a synergistic or additive 
fashion, while synergism is considered stronger than summation. On the 
other side, different compounds can also act in an antagonistic way, hence 
they weaken each other’s effect and may even lead to unwanted side-
effects [129]. 
2.1. Methotrexate 
MTX is the most prominent representative of the class of antifolates. As part 
of the large group of antimetabolites, these drugs were among the first 
subjects of research for the treatment of metastatic cancer and -as 
aforementioned, part of the first successful combination therapy regimen. 
MTX acts antagonistically to its structural analog FolA (compare Figure 3), 
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using the same mechanisms to enter the cell: It gets internalized by either 
reduced folate carrier (RFC) or FR [93, 130, 131]. Once in the cytosol, MTX 
competitively inhibits DHFR, which normally provides elementary 
components for the de novo synthesis of nucleic acids [110].  
Notably, MTX is not only used to treat multiple kinds of malignancies, in 
lower doses, its anti-inflammatory effect predominates [132]. Currently, it is 
of ubiquitous importance in the treatment of auto-immune diseases and 
although it was originally not designed to treat rheumatic arthritis, it is today 
the standard of care for this indication [133]. Despite its extensive use in the 
clinics, a major drawback, especially in monotherapy approaches, is the 
incidence of acquired resistance to MTX, which is clearly leading to a 
reduced applicability [134-136]. Therefore, MTX represents an ideal 
candidate for combination therapy. 
  
Figure 3: Chemical structures of A) folate and B) MTX as ligands of the 
folate receptor (FR). Dashed rings indicate structural differences. 
 
2.2. Pretubulysin 
Microtubules represent indispensable structures in eukaryotic cells. Their 
tasks comprise intracellular transport and cell movement. More importantly, 
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they represent essential components of the mitotic spindle apparatus, which 
is required to separate the chromosomes during mitosis. Microtubule 
targeting agents interfere with these processes by either stabilizing or 
destabilizing microtubule, thus hampering the cell division process, 
ultimately leading to G2/M arrest [137]. It is not surprising, that this class of 
therapeutics has been used widely in the clinics for numerous decades. 
However, they are also commonly facing resistance formation, which for 
instance is reported frequently for Vinca alkaloids [138, 139]. Therefore, the 
quest for new compounds of this effective class becomes more and more 
crucial. The tubulysins are a group of natural compounds, originally 
obtained from myxobacteria. Despite their great antitumoral efficiency, they 
are experiencing major drawbacks in regard of sufficient synthesis. 
Encouragingly, their bio-synthetical precursor pretubulysin (PT) can be 
synthesized with more convenience as it exhibits less complexity in its 
chemical structure (Figure 4) [140, 141]. Like the tubulysins, it binds to the 
vinca domain of ẞ-tubulin, effectively inhibiting tubulin polymerization which 
results in the disruption of the microtubule network and consequently 
apoptosis [142, 143]. Although its synthesis is facilitated in comparison to 
the tubulysins, PT exhibits a comparable therapeutic efficiency [140, 144]. 
PT reduces tumor cell growth of various cell lines [140], mediates inhibitory 
effects on cancer cell migration in vitro [144] and accomplishes promising 
effects in vivo: It shows significant anti-angiogenic effects [144, 145], 
prevents metastasis [140, 146] and inhibits tumor growth [140, 145, 147, 
148]. 
 
 
Figure 4: Chemical structure of Pretubulysin  
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3. Aims of this thesis 
3.1. Shielded and targeted nanoparticles for effective siRNA 
delivery 
siRNA is a rather novel, nevertheless powerful tool for the treatment of 
cancer. However, its delivery faces numerous obstacles, as siRNA by itself 
exhibits only short blood circulation times and is readily degraded by 
nucleases. In order to successfully deliver siRNA to its tumor site of action, 
stable nanoparticles had to be designed, which can be actively and 
passively targeted to tumor tissues. In this part, siRNA nanoparticles 
created using click chemistry to add shielding and FR targeting domains 
should be evaluated in terms of biodistribution and tumor gene silencing 
efficiency in a tumor mouse model. Furthermore, the aim was to investigate 
whether the novel shielding agent PSar could act as effective alternative to 
the well-established agent PEG in a biodistribution experiment. Moreover, 
antitumoral treatment experiments including the best performing formulation 
with siEG5 in combination with the natural microtubule inhibitor PT should 
be performed.  
3.2. Combinatorial treatment of PT and MTX  
Chemotherapy represents one of the most important elements in the 
treatment of cancer. Yet, monotherapy approaches are frequently 
hampered by arising resistances of cancer cells. Therefore, drug 
combinations are an encouraging alternative to monotherapy. The present 
work aimed to analyze the potentially beneficial combination effect of the 
novel antitubulin agent PT with the well-established cytostatic drug MTX in 
several approaches and tumor models.
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II. MICE, MATERIALS AND METHODS 
1. Mice 
1.1. Mouse strains 
1.1.1. NMRI-nude mice 
Female Rj: NMRI-Foxn1nu/Foxn1nu mice were obtained from Janvier Labs 
(Le Genest-St-Isle, France). Due to a defect in the Foxn1nu gene, this 
mutant outbred strain is characterized by thymic aplasia which leads to a 
lack of mature T-lymphocytes, while B-lymphocytes and all components of 
the innate immune system are perfectly functional. Also, the keratinization 
of hair follicle and epidermis is compromised. Thus, mice are nude, which 
makes them an ideal model for bioimaging experiments. More importantly, 
their immunodeficiency in terms of T-lymphocytes enables them as 
recipients for xenograft tumor models. 
1.1.2. BALB/c mice 
Female BALB/c mice were purchased from Janvier Labs (Le Genest-St-Isle, 
France). This inbred albino mouse strain possesses an intact innate and 
adaptive immune system. Mice are widely used e.g. in the fields of 
oncology, immunology or in cardiovascular research. They are well 
appreciated for their calm and gentle manner. Since mice are fully 
immunocompetent, they are used in our lab as sentinel animals for the 
quarterly health report. 
1.2. Housing conditions 
Animals were ordered at the age of 5 weeks and were allowed an 
acclimatization time of at least 7 days prior to experiments. They were 
housed in isolated ventilated cages (IVC type II, Tecniplast) under specific 
pathogen-free conditions, which were controlled quarterly by a complete 
health analysis of two sentinel animals. A 12 h day / night interval was 
provided and temperature as well as air humidity were kept constant at 24 
- 26°C, respectively 50 - 70% and recorded daily. Also, limits were set 
concerning light and sound intensities (200 Lux, respectively 40 dB). 
Stocking density of cages ranged from 2 to 5 mice and animal well-being 
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was controlled daily. Dust-free bedding was changed weekly and both food 
and water were provided sterilized and ad libitum. Moreover, cages were 
enriched with cottages, nest building material and wooden tubes. All criteria 
were in accordance with the official permission based on §11 of the German 
Animal Welfare Act (Tierschutzgesetz, [149]). 
1.3. Health monitoring 
In order to ensure specific pathogen-free conditions, quarterly health 
monitoring of our animal facility was performed. For this purpose, sentinel 
animals were kept in the same facility and received bedding material and 
food from all other animal cages once per week. After a period of 12 weeks, 
two sentinels were sent in for complete health analysis.  
 
2. Materials 
2.1. Cell culture 
Material Source 
Neuro-2a (N2a) cells 
(mouse neuroblastoma cells) 
American Type Cell Collection 
(ATCC) (Wesel, Germany) 
KB-wt cells  
(human cervix carcinoma cells) 
ATCC (Wesel, Germany) 
HUH7-wt cells 
(human hepatocellular carcinoma 
cells) 
NIBIO (Osaka, Japan)  
L1210 cells  
(mouse lymphocytic leukemia 
cells) 
kindly provided by Prof. Philip S. 
Low, Department of Chemistry 
(Purdue University, USA) 
RPMI 1640 medium Invitrogen (Karlsruhe, Germany) 
DMEM 1 g/l glucose medium Invitrogen (Karlsruhe, Germany) 
DMEM 4.5 g/l glucose medium Invitrogen (Karlsruhe, Germany) 
Ham’s F12 medium Invitrogen (Karlsruhe, Germany) 
FCS (fetal calf serum) Invitrogen (Karlsruhe, Germany) 
PBS (phosphate buffered saline) Biochrom (Berlin, Germany) 
TE (trypsin EDTA) solution Biochrom (Berlin, Germany) 
L-alanyl-L-glutamine Biochrom (Berlin, Germany) 
Cell culture plates and flasks TPP (Trasadingen, Switzerland) 
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2.2. In vivo experiments 
Material Source 
Isoflurane CP® CP-Pharma (Burgdorf, Germany) 
Bepanthen® 
Bayer Vital GmbH (Leverkusen, 
Germany) 
Syringes, needles BD Medical (Heidelberg, Germany) 
Multivette (EDTA-coated tubes) Sarstedt (Nümbrecht, Germany) 
HBG (HEPES buffered 5% 
glucose, pH 7.4) 
HEPES: Biomol (Hamburg, Germany) 
glucose monohydrate: Merck 
(Darmstadt, Germany) 
 
2.3. Oligomers 
Oligomers were synthesized by Dr. Philipp Klein (postdoc at Pharmaceutical 
Biotechnology, LMU) and Ines Truebenbach (PhD student at 
Pharmaceutical Biotechnology, LMU). 
Oligomer ID Sequence Topology 
1073 K(N3)-Y3-Stp2-K(G-SSBB-K-CholA2)-Stp2-Y3 T-shape 
1106 K(N3)-Y3-Stp2-K(G-K(CholA)2-Stp2-Y3 T-shape 
1169 K(N3)-Y3-Stp2-K(G-K(OleA)2-Stp2-Y3 T-shape 
1198 K(N3)-C-Y3-Stp2-K(K(OleA)2-Stp2-Y3-C T-shape 
951 C-STOTDA-K[K(PEG12-E4-MTX)2)2 4-arm 
454 C-Y3-Stp2-K(K-OleA2)-Stp2-Y3-C T-shape 
 
2.4. siRNAs  
Material Source 
siCtrl 
AuGuAuuGGccuGuAuuAG dTsdT 
CuAAuAcAGGCcAAuAcAU dTsdT 
Axolabs (Kulmbach, 
Germany) 
siEG5 
ucGAGAAucuAAAcuAAcu dTsdT 
AGUuAGUUuAGAUUCUCGA dTsdT 
Axolabs (Kulmbach, 
Germany) 
siAHA1-Cy7 
GGAuGAAGuGGAGAuuAGu dTsdT 
(Cy7)(NHC6)ACuAAUCUCcACUUcAUCC 
dTsdT 
Axolabs (Kulmbach, 
Germany) 
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* Capital letters: standard RNA ribonucleotides (A: Adenylate, G: Guanylate, 
C: Cytidylate, U: Uridylate); small letters: 2’methoxy-RNA; dT: DNA building 
block deoxy-thymidine; s: phosphorothioate linkage 
 
2.5. Compounds 
Pretubulysin (PT) 
synthesized by Dr. Jan Gorges (Institute for 
Organic Chemistry, Saarland University, 
Germany) 
Methotrexate (MTX) Sigma-Aldrich (Munich, Germany) 
 
2.6. Instruments 
Caliper DIGI-Met Preisser (Gammertingen, Germany) 
IVIS Lumina Caliper Life Science (Rüsselsheim, Germany) 
 
2.7. Software 
GraphPad Prism 5 
software 
GraphPad Software (San Diego, USA) 
Living Image 3.2 Caliper Life Science (Rüsselsheim, Germany) 
 
3. Methods 
3.1 . Cell culture 
Mouse neuroblastoma cells (Neuro-2a) were grown in Dulbecco’s modified 
Eagle’s medium (DMEM 1 g/l glucose), while murine lymphocytic leukemia 
cells (L1210) and human cervix carcinoma cells (KB) were cultured in RPMI 
1640 medium at 37°C in 5% CO₂ humidified atmosphere. Human 
hepatocellular carcinoma cells (HUH7) were cultured in 1:1 mixture of 
DMEM and Ham’s F12 medium. All media were supplemented with 10% 
fetal calf serum (FCS) and 4 mM stable glutamine.  
3.2. In vivo experiments  
For animal experiments, tumor cells were suspended in 150 µL PBS and 
were set subcutaneously into the left flank of 6 to 7-week-old NMRI nude 
mice using a 27G cannula. Inoculation of tumor cells was performed under 
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inhalation anesthesia using isoflurane in oxygen (3% for induction and 2.5% 
for maintenance). Animal well-being was controlled daily and weight was 
recorded every second day until tumors became measurable and from then 
on on a daily basis. Tumor sizes were determined by caliper and calculated 
[0.5 × longest diameter × shortest diameter2] as stated by Xu et al. [150]. 
Intratumoral injections were carried out under short narcosis, whereas 
intravenous injections did not require anesthesia and could be performed 
using a restrainer. For reasons of animal welfare, a maximum of 8 injections 
in total with 3 treatments per week was not exceeded. Furthermore, tails 
were thoroughly examined for injection-related lesions before every 
treatment. Animals were euthanized by cervical dislocation in isoflurane 
narcosis. Mice of all treatment experiments were sacrificed when previously 
determined termination criteria were reached. These included a tumor size 
of 1500 mm³ as well as severely affected well-being (indicated e.g. by 
continuous weight loss, apathy, visibly enlarged lymph nodes or spleen). 
All animal experiments were performed according to the terms stated in the 
proposal “Entwicklung von Sequenz-deﬁnierten Oligomeren als Träger für 
die zielgerichtete Einbringung neuer molekularer Therapeutika in Tumore“ 
(reference number: 55.2-1-54-2532-233-13), that was approved by the local 
animal ethics committee and the district government of Upper Bavaria on 
26 May 2014. All experiments complied with the guidelines contained in the 
German Animal Welfare Act [149]. 
3.2.1. Biodistribution study with PSar shielding 
Neuro-2a cells (5 × 10⁶) were injected subcutaneously into the left flank of 
7-week-old NMRI nude mice. When tumors reached 500 – 1000 mm³, 
animals were randomly divided into 3 groups (n=2) and injected 
intravenously with 250 µL of siRNA polyplex solution containing 50 µg of 
Cy7-labeled siRNA (N/P 10) with either PEG5k or PSar as shielding agent 
or HBG as buffer control. Mice were anesthetized with 3% isoflurane in 
oxygen and NIR fluorescence bioimaging was performed with a CCD 
camera at different time points over 24 h. Color bar scales were equalized 
and intensity of fluorescence signals was analyzed using the Living Image 
software 3.2. 
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3.2.2. Biodistribution of FolA-targeted lipopolyplexes 
L1210 cells (1 × 10⁶) were injected subcutaneously into the left flank of 
6-week-old NMRI nude mice. When tumors reached 500 mm³, animals were 
randomly divided into 7 groups (n=3) and injected intravenously with 250 µL 
of polyplex solution containing 50 µg of Cy7-labeled siRNA (N/P 10). 
Polyplex solution contained oligomers 1106 or 1169 modified with mono- or 
bis-DBCO, varying lengths of PEG and FolA targeting ligand. Mice were 
anesthetized with 3% isoflurane in oxygen and NIR fluorescence bioimaging 
was performed at different time points over 24 h using a CCD camera. 
Biodistribution was repeated in tumor-free mice, all other conditions 
remained unaffected. 
For the evaluation of acquired images, the efficiency of fluorescence signals 
was analyzed after color bar scales were equalized using the IVIS Lumina 
system with Living Image software 3.2 (Caliper Life Sciences, Hopkinton, 
MA, USA). 
3.2.3. Intratumoral EG5 gene silencing after systemic application 
Seven-week-old mice were subcutaneously injected with 1 × 10⁶ L1210 
cells and randomly divided into 4 groups (n=5) once their tumors reached 
500 mm³. Mice were administered intravenously 250 µL of 1106- or 1169- 
polyplex solution containing 50 µg of siCtrl or siEG5 (targeted and 
untargeted) at N/P 10. Control animals remained untreated but were 
otherwise handled the same way. The previously described formulations 
(see II.3.2.2.) were administered twice at daily interval via tail vein injection. 
Twenty-four hours after the second treatment, animals were sacrificed and 
tumors were harvested and homogenized. Subsequently, RNA was 
extracted using Trifast (Peqlab, Erlangen, Germany) according to the 
manufacturer’s protocol. Gene silencing efficiency was evaluated by Dr. 
Dian-Jang Lee (former PhD student at Pharmaceutical Biotechnology, 
LMU) as described in Klein et al.: Quantitative real-time polymerase chain 
reaction (qRT-PCR) was performed to determine the mRNA level of EG5 in 
the tumor samples. One milligram of total RNA was used to generate cDNA 
using qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, USA). 
Quantitative RT-PCR was performed on a LightCycler 480 system (Roche, 
Mannheim, Germany) using UPL Probes (Roche, Mannheim, Germany) 
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and Probes Master (Roche, Mannheim, Germany) with GADPH as 
housekeeping gene. The following probes and primer sequences were 
used: murine GAPDH (ready-to-use in UPL), and EG5 (UPL Probe #100) 
forward: (TTCCCCTG CATCTTTCAATC, reverse: TTCAGGCTTATTCATT 
ATGTTCTTTG). Results were analyzed by the DCT method. CT values of 
GAPDH were subtracted from CT values of EG5. DCT values of treated 
animals were calculated as percentage of untreated control animals [147]. 
3.2.4. Clinical biochemistry after systemic application  
Tumor-free animals (n=4-5 mice per group) were either injected with 250 µL 
of the best performing formulation (1106 DBCO2-ss2-PEG24-FolA) or 
remained untreated. At 48 h post injection, all mice were sacrificed by 
cervical dislocation and final heart puncture was performed to obtain blood 
for clinical biochemistry analysis. Blood was collected in EDTA-coated tubes 
and centrifuged instantly at 800 × g for 7 min to isolate blood plasma. The 
supernatant was analyzed regarding renal (creatinine, blood urea nitrogen) 
and liver parameters (alanine aminotransferase, aspartate 
aminotransferase) in the Clinic of Small Animal Medicine, Faculty of 
Veterinary Medicine, LMU Munich. Untreated control animals served as 
reference. 
3.2.5. Combinatorial treatment with FolA-targeted siEG5 
lipopolyplexes and PT 
Three days after subcutaneous tumor cell inoculation (0.5 × 10⁶ L1210 
cells), mice were randomly distributed into six groups (n=6) and injected 
intravenously with 250 µL of siRNA formulations (50 µg of siEG5 or siCtrl) 
with or without co-treatment with PT (2 mg/kg) respectively plain PT or HBG. 
Treatments were repeated 3 times per week (on days 3, 5, 7, 10, 12, 14, 17 
and 19) with a maximum of 8 injections. Animals were sacrificed when they 
reached the previously determined termination criteria and Kaplan Meier 
survival analysis was compiled. 
3.2.6. Treatment with GE11-targeted, PT containing siEG5 
lipopolyplexes 
Seven-week-old NMRI nude mice were inoculated with 5 × 10⁶ HUH7 cells. 
After sufficient tumor growth (200 - 250 mm³), treatments were started 
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individually. Animals were randomly divided into 6 groups (n=6) and injected 
via tail vein injection with 250 µL of siRNA formulations (50 µg of siEG5 or 
siCtrl) with or without co-administration with PT (2 mg/kg) respectively plain 
PT or HBG. Treatments were performed 8 times at most with 3 injections 
per week. Animals were sacrificed when they reached the previously 
determined termination criteria and Kaplan Meier survival analysis was 
carried out. 
3.2.7. Intratumoral treatment with E4-MTX-H-PT conjugate 
KB cells (5 × 10⁶) were set subcutaneously into the left flank of 7-week-old 
NMRI nude mice. Two days after tumor cell inoculation, the animals were 
randomly divided into 4 groups (n=8) and injected intratumorally under 
general anesthesia with 50 µL of either E4-MTX (2.7 mg/kg), native PT 
(PT-COOH, 2 mg/kg) or the analogous conjugate. The untreated group did 
not receive any injections. Treatments were performed 6 times (on days 2, 
5, 7, 9, 12 and 14) for all animals. Animals were sacrificed when they 
reached the previously determined termination criteria. 
3.2.8. Effect of intravenous injections of PT+MTX on L1210 tumor 
growth  
L1210 cells (0.5 × 10⁶) were injected subcutaneously into the left flank of 
6-week-old NMRI nude mice. On day three after tumor cell inoculation, the 
animals were randomly divided into 4 groups (n=4) and injected 
intravenously with 250 µL of PT (2 mg/kg), MTX (5 mg/kg), the 
corresponding combination (PT+MTX) or HBG. Treatments were repeated 
3 times per week (on days 5, 7, 10, 12, 14, 17 and 19). When mice reached 
the previously determined termination criteria, the experiment was ended 
by cervical dislocation. All MTX-treated animals were sacrificed on day 14, 
together with the animals of MTX dose finding experiment. Due to its tumor 
burden, one animal of MTX group had to be sacrificed ahead of schedule 
on day 13. 
3.2.8.1. MTX dose finding 
Experiment was performed in two sections under equal conditions. 
Six-week-old animals were injected subcutaneously with 0.5 × 10⁶ L1210 
cells and randomly distributed into 4 respectively 6 groups. In the first 
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section, low doses of MTX were compared to HBG. Therefore, mice were 
treated with 2.5, 5, 7, 10 or 20 mg/kg MTX. In the second section, higher 
doses of 40, 80 and 100 mg/kg MTX were compared to HBG. Injections 
were performed trice weekly, starting on day three with a maximum of 
7 injections. Mice treated with lower doses of MTX were sacrificed 
collectively on day 14, whereas animals treated with higher doses were 
euthanized when termination criteria were reached, respectively. 
3.2.9. Effect of intravenous injections of PT+MTX on KB tumor 
growth  
KB cells (5 × 10⁶) were injected subcutaneously into the left flank of 
7-week-old NMRI nude mice. When tumors reached 200 – 250 mm³, 
treatments were started individually. Animals were randomly divided into 
4 groups (n=4) and injected intravenously with 250 µL of PT (2 mg/kg), 
MTX (5 mg/kg), the corresponding combination (PT+MTX) or HBG. 
Treatments were repeated 3 times per week with a maximum of 8 injections. 
Animals were euthanized when termination criteria were reached, 
respectively. 
3.2.10. Effect of intravenous injections of PT+MTX on HUH7 tumor 
growth 
Seven-week-old NMRI nude mice were inoculated subcutaneously with 
HUH7 cells (5 × 10⁶). Animals were divided into 4 groups (n=4) and 
treatments were started individually once tumors reached 200 – 250 mm³. 
Systemic applications with 250 µL of PT (2 mg/kg), MTX (5 mg/kg), the 
combination of both (PT+MTX) or HBG were performed thrice weekly for up 
to 8 injections. Mice were sacrificed by cervical dislocation after mice 
reached the previously determined termination criteria, respectively. Kaplan 
Meier survival analysis was carried out. 
3.2.11. Oligomer-based micellar encapsulation of PT+MTX for 
systemic administration 
L1210 cells (0.5 × 10⁶) were implanted subcutaneously into the left flank of 
6-week-old NMRI nude mice. On day three after tumor cell implantation, 
animals were randomly divided into 7 groups (n=6) and injected 
intravenously with 250 µL of PT (2 mg/kg), PT+MTX (2 mg/kg PT, 
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2.5 mg/kg MTX), the corresponding groups with 454, 454 alone, 
454 MTX (2.5 mg/kg MTX) or HBG. Treatments were performed 3 times per 
week (on days 3, 5, 7, 10, 12, 14, 17 and 19). Animals were euthanized by 
cervical dislocation, as soon as the previously determined termination 
criteria were reached and Kaplan Meier survival analysis was compiled. 
 
3.3. Statistical analysis 
Results are expressed as mean + S.E.M. if not indicated elsewise. 
Statistical analysis was performed with unpaired students t-test and log-rank 
test using GraphPad Prism™ and p-values < 0.05 were considered as 
significant (*p < 0.05; **p < 0.01; ***p < 0.001; ns = not significant).
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III. RESULTS 
1. Shielded and targeted lipopolyplexes for effective 
siRNA delivery  
For efficient siRNA delivery, a suitable carrier system is required. In 
previous work, a library containing more than 1200 sequence-defined 
oligomers was established. This chapter presents the optimization of a 
siRNA carrier system in terms of stability, body circulation and tissue 
specific accumulation by functionalization with shielding and targeting 
agents. Moreover, properties like gene silencing efficiency and therapeutic 
potential were evaluated. 
The PSar biodistribution experiment was performed together with Dr. Eva 
Kessel (former veterinary MD student at Pharmaceutical Biotechnology, 
LMU). Experiments with oligomers 1106 and 1169 were performed in 
cooperation with Dr. Dian-Jang Lee (former PhD student at Pharmaceutical 
Biotechnology, LMU). Johannes Schmaus (veterinary MD student at 
Pharmaceutical Biotechnology, LMU) assisted during FolA + siEG5 + PT 
treatment experiment. All experiments were carried out in NMRI nude mice. 
1.1. Exploiting click chemistry for the modification of 
lipopolyplexes with functional domains 
Previously, a new class of very effective carrier systems was designed by 
our group. These redox-sensitive lipo-oligomers proved to be very valuable 
for the delivery of siRNA [49]. The best-performing oligomer of this study, 
the T-shaped oligomer T-0N3 (ID number: 992, see Figure 5, table top) was 
chosen as lead structure for further optimization by surface-
functionalization. Therefore, T-0N3 was further equipped with one (T-1N3, 
ID 1073) or two (T-2N3, ID 1086) click-reactive azide groups, serving as 
anchor points for attaching additional units. The azide function enables the 
particle for bio-orthogonal click reactions with cyclooctyne derivates, like 
dibenzocyclooctyne (DBCO). This reaction between a cyclooctyne and an 
azide group proceeds effectively without the need for a catalyst, does not 
produce any side products and - as it works without copper, it does not 
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cause cytotoxicity [151-153]. The reaction was performed after the 
formation of siRNA lipopolyplexes. Therefore, surface-functionalization, for 
instance with shielding domains, could be introduced onto the 
nanoparticular siRNA formulation. In addition to the shielding agent 
polyethylene glycol (PEG), which is the gold standard among shielding 
agents, polysarcosine (PSar) was investigated as alternative shielding 
agent. PSar was described to work efficiently while being well tolerated [75-
77]. The current work used it C-terminally functionalized with DBCO 
(DBCO-PSar - Figure 5, table bottom). Besides its shielding ability, the 
DBCO-PSar unit enables the introduction of targeting ligands via its 
N-terminal amino group. Hence, lipopolyplexes can be further equipped for 
example with FolA for active targeting.  
Particles were evaluated in vitro to choose the most suitable candidate for 
in vivo studies. Gel retardation assays and cell studies revealed a strong 
reduction of cellular binding and uptake of PSar-shielded particles, which 
was most pronounced in case of T-1N3 (1073) [154]. 
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Figure 5: Graphical illustration of compounds for lipoplex formation. 
Table top: Variants of T-shaped oligomers with increasing amounts of 
terminal azidolysines: T-0N3 (ID: 992 published in [49]), T-1N3 (ID: 1073) 
and T-2N3 (ID: 1086). Further units of the oligomers: Y: tyrosine, K: lysine, 
G: glycine, Stp: succinoyl-tetraethylene-pentamine, ssbb: succinoyl-
cystamine, CholA: 5β-cholanic acid, N3: azide function. Table bottom: 
Chemical structure of different DBCO-PSar shielding domains: 
DBCO-PSar119, acetylated DBCO-PSar119-Ac and FolA-targeted 
DBCO-PSar110-FolA. Scheme: Simplified illustration of the synthesis of a 
DBCO-PSar-shielded polyplex. The figure is provided by Klein et al. [154]. 
 
1.1.1. Comparison of PSar and PEG as shielding agents 
The in vivo setting aimed for a direct comparison of the shielding capacity 
of PEG and PSar. For this purpose, the candidate with best shielding 
properties in the in vitro experiments, T-1N3 (ID: 1073 [154]) was surface-
modified with either DBCO-PEG5k or acetylated PSar (DBCO-PSar119-Ac). 
The acetylated PSar agent without terminal cationic charge was chosen for 
better comparability with the commercial PEG agent. 
Biodistribution studies were performed using Neuro-2a tumor bearing mice. 
Two animals per group were injected intravenously with either the 
unshielded polyplex, or the formulation shielded with DBCO-PEG5k 
respectively DBCO-PSar119-Ac. Near infrared (NIR) imaging was performed 
immediately and repeated at various time points until 24 h. 
Figure 6 depicts the formulations’ biodistribution. At 15 min post injection, 
the unshielded formulation started accumulating in the liver. However, in 
case of both shielded formulations, circulation could largely be enhanced, 
leading to a biodistribution of the whole body which was still visible after 1 h. 
After 4 h, intensity was notably reduced in all groups. Yet, peripheral body 
parts like paws still showed strong fluorescence signal. The lack of tumor 
accumulation after 4 h and the dominant bladder signal at that time point 
indicate renal clearance, impeding passive targeting via the EPR effect 
[154].  
In sum, direct comparison of PEG and PSar shielding of polyplexes 
revealed only minor variations in terms of circulation or tumoral retention of 
the formulation. However, both shielding options clearly increased the 
formulation’s circulation time in comparison to the unshielded control [154]. 
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Figure 6: In vivo distribution of polyplexes with different forms of 
shielding in Neuro-2a tumor bearing mice. Unshielded polyplexes (top), 
PEG-shielded (middle) or PSar-shielded polyplexes (bottom) were 
injected intravenously and NIR fluorescence bioimaging was performed 
immediately and repeated at multiple time points until 24 h. Mice are 
presented in dorsal, ventral and lateral view. Color scale (efficiency) had a 
minimum of 1.6 e-5 and a maximum of 2.2 e-4 fluorescent photons/incident 
excitation photon. Illustration is provided by Klein et al. [154]. 
 
1.2. FolA receptor-targeted lipopolyplexes for gene silencing in 
vivo 
Besides shielding with PEG or alternatives like PSar, also tumor targeting 
has a great influence on a formulation’s performance after systemic 
application in tumor bearing mice. Active targeting enables not only the 
direction of a nanoparticle to its site of action, but also its internalization into 
the target cell [155]. Therefore, nanoparticles in the following experiments 
were equipped with FolA for selective siRNA delivery to FR-overexpressing 
L1210 cells. 
Based on the successful application of lipopolyplexes with click-reactive 
introduction of functional domains in the previous part (see III.1.1.1., [154]), 
click chemistry was again exploited for the following experiments. Via 
solid-phase supported synthesis, a sequence-defined lipo-oligomer was 
designed. The T-shaped oligomer 991 was chosen to build the particle’s 
core. It comprises two cholanic acid (CholA) chains and tyrosine units 
promoting polyplex stability, resulting in stable polyplexes with beneficial 
carrier properties [49]. To enable click-reactive modification with functional 
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domains, the oligomer was further refined by adding an azido function (new 
oligomer ID 1106). Subsequently, mono- and bivalent attachments of DBCO 
with varying PEG lengths were introduced and particles were equipped with 
FolA as targeting ligand (Figure 7, [147]). 
 
Figure 7: Chemical composition of a PEG-shielded, FolA-targeted lipo-
oligomer. Top: Schematic illustration of the T-shaped oligomer (ID 1106). 
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Abbreviations of individual units indicate: Y: tyrosine, K: lysine, G: glycine, 
Stp: succinoyl-tetraethylene-pentamine, CholA: 5β-cholanic acid, N3: azide 
function. Middle: Chemical structure of non-targeting DBCO-PEG units: 
Shorter DBCO-PEG24, longer DBCO-PEG5k and double-click 
DBCO2-ss2-PEG24. Bottom: Chemical structure of FolA-targeting 
DBCO-units with mono- or bis-DBCO and varying PEG-lengths. The figure 
was adapted from Klein et al. [147]. 
 
1.2.1. Biodistribution study 
Biodistribution of lipopolyplexes for effective siRNA delivery depends on 
various factors. To evaluate the formulation’s distribution properties after 
intravenous injection, fluorescence imaging was performed. 
In this experiment, the FR-positive L1210 murine lymphocytic leukemia 
tumor model was chosen. When tumors reached 500 – 1000 mm³, animals 
were injected via tail vein with the previously synthesized T-shaped 
oligomer 1106 modified with mono- or bis-DBCO with varying PEG lengths 
for surface shielding. Moreover, some formulations were functionalized with 
the targeting ligand FolA for selective delivery to L1210 cells.  
After the injection of (50% Cy7-labeled) siRNA formulations, the fluorescent 
dye was monitored using near infrared (NIR) bioimaging. Biodistribution was 
analyzed at various time points until 24 h after injection. 
Figure 8 shows the biodistribution of formulations. Unshielded polyplexes 
accumulated mainly in the liver and blood circulation could not be improved 
by modification with DBCO-PEG24. However, when mono-DBCO was 
replaced by bis-DBCO, biodistribution could largely be enhanced. 
Moreover, the functionalization with FolA prolonged in vivo circulation in 
both mono- and bis-DBCO formulations. Tumor accumulation could be 
demonstrated in all FolA-targeted groups and also in the unshielded group 
after 4 h. The best all over biodistribution with fluorescence signals in most 
body parts after 4 h was achieved by DBCO2-ss2-PEG24 FolA formulation. 
As shielding can have an impact on blood circulation, clearance and half life 
time [50-52], different PEG lengths were investigated. For this purpose, 
3 animals per group were injected with the same formulations as before, but 
modified with longer PEG chains: DBCO-PEG5k respectively 
DBCO-PEG72 FolA or DBCO2-ss2-PEG72 FolA. The untargeted, 
III. Results     31 
PEG5k-shielded formulation could improve circulation as compared to the 
unshielded polyplex. Also, strong fluorescence signal was found at 
superficial peripheral sites like paws after 4 h. Consistent with our findings 
with mono- and bis-DBCO in PEG24 FolA groups, bis-DBCO was clearly 
superior to mono-DBCO in PEG72 FolA formulations in terms of blood 
circulation. DBCO-PEG72 FolA showed weaker biodistribution than the 
untargeted DBCO-PEG5k formulation. In case of the bis-DBCO containing 
equivalent, fluorescence signal could first be detected in the lung area and 
started spreading to the whole body just after 2 h. Subsequently, it was 
distributed to the whole body, yet lacking tumor accumulation that was 
shown for the shorter PEG24 analog.  
In sum, the superiority of shorter PEG24 chains over longer PEG5k or PEG72 
chains regarding tumor accumulation and circulation time was 
demonstrated. 
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Figure 8: Evaluation of in vivo distribution of lipopolyplexes in L1210 
tumor bearing mice. Bioimaging of lipopolyplexes (50% Cy7-labeled siRNA) 
without shielding or modified with mono- or bis-DBCO and varying PEG-
lengths in a FolA-targeted and a non-targeted version, were determined by 
NIR fluorescence bioimaging. Mice were injected intravenously and imaging 
was performed immediately and repeated after 15 and 30 min and 1, 2, 3, 
4 and 24 h. Experiment was performed with 3 animals per group for time 
points until 1 h, one animal at 2 and 3 h and two animals at 4 and 24 h. One 
representative animal per group and time point is shown. Animals are 
presented in lateral position allowing the observation of the tumor site 
(indicated by green circles). Color scale (efficiency) had a minimum of 
1.2 e-5 and a maximum of 3.3 e-4 fluorescent photons/incident excitation 
photon. A) Formulations with shorter PEG- (PEG24) chain. B) Formulations 
with longer PEG- (PEG5k / PEG72) chain. Figure is adapted from Klein et al. 
[147]. 
 
 
A formulation’s elimination from blood circulation can be evaluated when 
animals are imaged in ventral position. Figure 9 shows major accumulation 
of lipopolyplexes in the liver area starting already after 30 min in case of 
DBCO-PEG24 and after 1 h in the unshielded group. The only groups with 
whole body distribution after 4 h are double-click (DBCO2) FolA-targeted 
formulations. Liver signal is eventually decreasing after 24 h in all groups 
besides DBCO-PEG24 and DBCO-PEG5k in which it has already been 
cleared before. Elimination from blood circulation occurs through renal 
clearance which is indicated by a strong fluorescence signal in the bladder 
area. It appears after 1 h in the unshielded group, also in the DBCO-PEG24 
and DBCO-PEG72 FolA groups, while in most other groups it becomes 
visible after 4 h. Only in DBCO2-ss2-PEG24 FolA injected animals, no 
obvious bladder signal is detectable after 4 h, as fluorescence is still 
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detectable in the whole body. 
Summing up all findings, 1106 DBCO2-ss2-PEG24 FolA demonstrated 
superior biodistribution properties. It exhibited the longest circulation time 
as well as tumor accumulation and latest clearance of all tested 
formulations.  
 
 
 
 
Figure 9: Elimination of lipopolyplexes from the blood circulation after 
i.v. injection in L1210 tumor bearing mice. Bioimaging of lipopolyplexes 
(50% Cy7-labeled siRNA) with varying PEG lengths and modified with 
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mono- or bis-DBCO in a FolA-targeted and a non-targeted version, were 
determined by NIR fluorescence bioimaging. Mice were injected 
intravenously and imaging was performed immediately and repeated after 
15 and 30 min and 1, 2, 3, 4 and 24 h. Experiment was performed with 
3 animals per group for time points until 1 h, one animal at 2 and 3 h and 
two animals at 4 and 24 h. One representative animal per group and time 
point is shown. Animals are presented in ventral view allowing the 
observation of the liver (indicated by orange arrows) and bladder (indicated 
by yellow arrows) to analyze the formulation’s clearance. Color scale 
(efficiency) had a minimum of 1.2 e-5 and a maximum of 3.3 e-4 fluorescent 
photons/incident excitation photon. A) Formulations with shorter PEG- 
(PEG24) chain. B) Formulations with longer PEG- (PEG5k / PEG72) chain.  
 
 
 
To evaluate the reason behind the obvious improvement of biodistribution 
through modification with FolA as targeting ligand, the experiment was 
repeated with the best-performing formulation in tumor-free animals. 
Figure 10 depicts a comparison of L1210 tumor bearing mice to tumor-free 
mice. Biodistribution of DBCO2-ss2-PEG24 FolA is not as broad as in L1210 
tumor bearing animals. Yet, the detectable fluorescence pattern is 
comparable to the untargeted DBCO2-ss2-PEG24 [147]. 
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Figure 10: Time-dependent distribution of 1106 DBCO2-ss2-PEG24 FolA 
in tumor-free mice compared to L1210 tumor bearing mice at different time 
points after intravenous injection. NIR imaging of 50% Cy7-labeled siRNA 
polyplexes was performed at 0, 15 and 30 min, 1, 2, 3, 4 and 24 h after 
systemic administration. The experiment was performed with 3 animals per 
group for time points until 1 h, one animal at 2 and 3 h and two animals at 
4 and 24 h. One representative animal per group and time point is shown. 
Color scale (efficiency) had a minimum of 1.2 e-5 and a maximum of 3.3 e-4 
fluorescent photons/incident excitation photon. A) Comparison of 
tumor-free animals to L1210 tumor bearing animals in lateral view. 
B) Comparison of tumor-free animals to L1210 tumor bearing animals in 
ventral view allowing the observation of the liver (indicated by orange 
arrows) and bladder (indicated by yellow arrows) to analyze the 
formulation’s clearance. Panel B) is adapted from Klein et al. [147]. 
 
Fatty acids or cholanic acids are contained in the lipo-oligomer core for 
hydrophobic stabilization. To evaluate the impact of different acids, cholanic 
acid (CholA) was replaced by oleic acid (OleA), which has been used with 
FolA-targeted formulations in previous work [156, 157]. Therefore, an 
additional experiment with the modified oligomer (new oligomer ID 1169) 
was performed. Analog to the first part, L1210 tumor bearing mice were 
injected with DBCO2-ss2-PEG24 FolA and fluorescence bioimaging was 
performed at various time points. Figure 11 shows the biodistribution of 
injected animals. Although the distribution pattern looks similar to 1106 until 
3 h, no advantage of OleA over CholA could be demonstrated. 
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Figure 11: Comparison of time dependent distribution of 1106 and 
1169 formulations. The upper panel shows DBCO2-ss2-PEG24 FolA 
formulation with the CholA-containing oligomer 1106, whereas the lower 
panel shows the analog (OleA-containing) 1169 formulation. L1210 tumor 
bearing mice were injected intravenously and NIR imaging of 50% 
Cy7-labeled siRNA polyplexes was performed at 0, 15 and 30 min, 1, 2, 3, 
4 and 24 h after systemic administration. The experiment was performed 
with 3 animals per group for time points until 1 h, one animal at 2 and 3 h 
and two animals at 4 and 24 h. One representative animal per group and 
time point is shown. Color scale (efficiency) had a minimum of 1.2 e-5 and a 
maximum of 3.3 e-4 fluorescent photons/incident excitation photon. A) 
Lateral view of the mice is presented, allowing the observation of the tumor 
site (indicated by green circles) B) Mice are presented in ventral view 
allowing the observation of the liver (indicated by orange arrows) and 
bladder (indicated by yellow arrows) to analyze the formulation’s clearance. 
Panel A) is adapted from Klein et al. [147]. 
 
1.2.2. Clinical biochemistry evaluation 
Systemic administration of formulations always bears a risk of undesired 
side effects when non-target tissue is reached. To evaluate whether our 
lipopolyplex was tolerated well by the animals, clinical biochemistry of blood 
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samples was analyzed regarding renal and liver parameters which are 
altered frequently and showed high amounts of fluorescence signal in the 
biodistribution study. Tumor-free animals were used for this experiment as 
L1210 tumors tend to metastasize rapidly and by that influence especially 
liver parameters. Mice were injected intravenously with 
1106 DBCO2-ss2-PEG24 FolA. At 24 h later, animals were sacrificed and 
blood was obtained. Subsequently, plasma was analyzed for renal 
parameters BUN (blood urea nitrogen) and creatinine and liver parameters 
AST (aspartate aminotransferase) and ALT (alanine aminotransferase). 
Comparing the values to untreated tumor-free animals, all parameters were 
within normal limits, indicating a good tolerance of the formulation 
(Figure 12). 
 
Figure 12: Clinical biochemistry parameters (renal parameters 
creatinine and BUN, liver parameters ALT and AST). Tumor-free mice 
injected with 1106 DBCO2-ss2-PEG24 FolA were compared to an internal 
untreated control group which was otherwise handled in the same way and 
time schedule. Plasma was obtained when animals were sacrificed and 
subsequently analyzed in the Clinic of Small Animal Medicine, Centre for 
Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich. 
Represented is the mean + S.E.M. of 4-5 mice per group. Illustration is 
adapted from Klein et al. [147]. 
 
1.2.3. Tumoral gene silencing in vivo 
While fluorescence imaging of Cy7-labeled formulations can only provide 
information about the distribution pattern, no statement can be made 
regarding cellular uptake. As siRNA acts in the cytosol, downregulation of a 
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target gene product implies successful uptake. Hence, an experiment was 
performed to evaluate gene silencing efficiency of the best performing 
formulation of our biodistribution experiment. DBCO2-ss2-PEG24 FolA was 
chosen, since it showed tumor accumulation until 4 h post injection. 
Lipopolyplexes were prepared with 1106 and siRNA directed against mRNA 
of the kinesin-related motor protein EG5. By directing EG5, mitosis of cells 
gets inhibited. As a control, polyplexes were prepared with siCtrl. Also, the 
untargeted formulation with siEG5 was evaluated for its gene silencing 
efficacy. Mice bearing L1210 tumors were randomly divided into 4 groups 
when tumors reached 500 mm³ and intravenous injections were performed 
twice at 24 h interval. At 48 h after the first treatment, animals were 
sacrificed and tumors were harvested for RNA extraction and qRT-PCR 
analysis of mRNA levels of EG5. mRNA levels of treatment groups were 
eventually compared to untreated animals. 
Treatment with 1106 DBCO2-ss2-PEG24 FolA + siEG5 significantly reduced 
tumoral EG5 mRNA expression (~60%). In case of the siCtrl containing 
targeted analog, EG5 downregulation was only weak. Also, the untargeted 
DBCO2-ss2-PEG24 + siEG5 formulation mediated only neglectable effects 
regarding EG5 downregulation (Figure 13). 
 
Figure 13: Gene silencing efficiency of 1106 formulations in L1210 
tumor bearing mice. Groups (n=5 animals per group) were treated with 
1106 DBCO2-ss2-PEG24 FolA with siEG5 or siCtrl or the siEG5 containing 
untargeted analog. Animals were sacrificed 24 h after twofold intravenous 
injection and tumors were harvested for qRT-PCR analysis of mRNA levels 
of EG5 gene. EG5 mRNA levels (mean + S.E.M.) are expressed in % of 
untreated control. qRT-PCR was performed by Dr. Dian Jang Lee (former 
PhD student at Pharmaceutical Biotechnology, LMU). Figure is adapted 
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from Klein et al. [147]. 
 
The evaluation of gene silencing efficiency was repeated with the OleA 
containing 1169 oligomer to analyze the impact of different fatty or bile acids 
on gene silencing efficiency. Experimental settings were identical to the first 
part with 1106 oligomer.  
Tendencies between the different formulations were similar to the CholA 
containing oligomer 1106. Yet, EG5 downregulation by 
1169 DBCO2-ss2-PEG24 FolA + siEG5 did not reach statistical significance 
(~40%) (Figure 14). This confirmed the superiority of CholA over OleA that 
was already demonstrated during biodistribution studies (Figure 11). 
 
Figure 14: Gene silencing efficiency of 1169 formulations in L1210 
tumor bearing mice. Groups (n=5 animals per group) were treated with 
1169 DBCO2-ss2-PEG24 FolA with siEG5 or siCtrl or the siEG5 containing 
untargeted analog. Animals were sacrificed 24 h after twofold intravenous 
injection and tumors were harvested for qRT-PCR analysis of mRNA levels 
of EG5 gene. EG5 mRNA levels (mean + S.E.M.) are expressed in % of 
untreated control. qRT-PCR was performed by Dr. Dian Jang Lee (former 
PhD student at Pharmaceutical Biotechnology, LMU). Figure is adapted 
from Klein et al. [147]. 
 
 
During both experimental parts, the animals’ weight was recorded to monitor 
animal well-being especially during treatments. In case of 1106, no effect of 
the injections could be observed, while minor weight loss occurred after the 
first treatment with 1169 formulations (Figure 15).  
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Figure 15: Weight of mice during gene silencing experiments, starting 
with L1210 tumor cell inoculation (day 0) and ending with euthanasia. 
Represented is the mean + S.E.M. of 5 mice per group. A) Intravenous 
injections with 1106 formulations are indicated by blue (group 2) and black 
(group 3 + 4) arrows. B) Intravenous injections with 1169 formulations are 
indicated by black arrows (groups 2, 3, 4). Illustration A) is adapted from 
Klein et al. [147]. 
 
 
In sum, 1106 oligomer modified with bis-DBCO, short PEG24 and FolA-
targeting proved to be superior in biodistribution studies and blood 
parameters were unobtrusive in consequence of intravenous treatments. 
Furthermore, the same formulation in combination with EG5 siRNA 
mediated significant downregulation of EG5 mRNA in L1210 tumors. 
Therefore, it presents an attractive candidate for an in vivo treatment 
experiment. 
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1.2.4. Combinatorial treatment with FolA-targeted lipopolyplexes 
and PT 
Building on these encouraging results, a treatment experiment with 
systemic administration was designed to analyze the therapeutic potential 
of 1106 DBCO2-ss2-PEG24-FolA with siEG5. Furthermore, the novel 
microtubule inhibitor pretubulysin (PT) was chosen for a combination 
therapy approach. 
The aforementioned formulation was compared to the corresponding 
formulation with siCtrl and both groups were further modified with PT, while 
free PT and HBG served as controls. 
The dose of PT was chosen based on previous combination treatment 
experiments with up to 8 intravenous injections of PT at a dose of 2 mg/kg, 
in which effective tumor growth inhibition was achieved in absence of any 
systemic side effects (see III.2.2. and III.2.3.). Therefore, the current study 
was carried out with the same dose. 
L1210 tumor bearing mice were treated intravenously for up to 8 times, 
starting on day 3. On day 8, tumors of all groups lacking PT became 
measurable. Subsequently, tumors of HBG and siCtrl group grew rapidly. 
All PT containing groups revealed distinct tumor growth inhibition. Within 
these groups, siCtrl + PT mediated a weaker antitumoral effect than free 
PT, while siEG5 + PT led to the most efficient tumor growth inhibition 
(Figure 16). 
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Figure 16: Tumor growth of L1210 tumor bearing mice treated with HBG, 
free PT or siEG5 respectively siCtrl containing formulations with or without 
PT. A) Tumor growth curve, day 0 represents the day of tumor cell 
inoculation. Treatments are indicated by black arrows (mean + S.E.M.; n=6; 
*p < 0.05, **p < 0.01, ***p < 0.001). B) Comparison of tumor sizes of 
PT-containing groups on day 22 (mean + S.E.M.; n=6; *p < 0.05, **p < 0.01, 
***p < 0.001). A) Illustration is adapted from Klein et al. [147]. 
 
 
Animals were sacrificed after they reached the previously determined 
termination criteria and Kaplan Meier survival analysis was compiled 
(Figure 17, [147]). While the overall survival in PT-free groups ranged from 
12 (HBG and siCtrl) to 14 (siEG5) days after rapid tumor progression, all 
PT-containing groups survived significantly longer. The first animal of 
siCtrl + PT group was sacrificed on day 22, whereas treatments with free PT 
resulted in a survival of all animals until day 24. siEG5 + PT group achieved 
an overall survival until day 28, when all animals of the remaining groups 
were already sacrificed. This resulted in a significantly prolonged survival of 
this group (log rank test of Kaplan Meier curve PT vs. siEG5 + PT: 0.0021; 
Mean survival PT vs. siEG5 + PT: 0.0036).  
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Figure 17: Survival of mice treated with HBG, free PT or 
1106 DBCO2-ss2-PEG24 FolA + siEG5 respectively siCtrl formulations with 
and without combination with PT. A) Kaplan Meier survival analysis of 
indicated groups (n=6; **p < 0.01). B) Mean survival of indicated groups 
(mean + S.E.M.; n=6; **p < 0.01, ***p < 0.001). Panel A) is adapted from 
Klein et al. [147]. 
 
To ensure animal well-being, mice were controlled daily and weight was 
recorded. The even weight development of all groups, which is depicted in 
Figure 18, indicates that treatments were tolerated well by the animals. 
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Figure 18: Weight development of L1210 tumor bearing mice treated with 
HBG, free PT or siEG5 respectively siCtrl containing formulations with or 
without PT. Day 0 represents the day of tumor cell inoculation. Treatments 
are indicated by black arrows (mean + S.E.M.; n=6). Graph is adapted from 
Klein et al. [147]. 
 
To conclude, significantly inhibited tumor growth and prolonged survival was 
demonstrated, in absence of any systemic side effects after multiple 
intravenous injections with the FolA targeted siEG5 formulation in 
combination with PT. 
 
1.2.5. Treatment with GE11-targeted, PT containing siEG5 
lipopolyplexes 
The next aim was to evaluate whether the promising results of siEG5 and 
PT combination can be reproduced in another tumor model. For this 
purpose, NMRI-nu/nu mice were inoculated with human HUH7-wt 
hepatoma cells. HUH7 cells overexpress the EGF receptor. Therefore, a 
different carrier system was selected, which is targeted to the EGF receptor. 
Based on its very encouraging transfection efficiency in vitro, the T-shaped 
oligomer 1198 was chosen from our library (Figure 19). This lipo-oligomer 
emerged from oligomer 454, which was previously used in other animal 
experiments (see III.2.3.). However, it was additionally equipped with an 
azide for click chemistry. Thus, siRNA lipopolyplexes of 1198 can be 
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reacted with DBCO-PEG24-GE11 to introduce PEG as shielding agent and 
the peptide GE11 as EGFR targeting ligand. The oligomer was formulated 
together with EG5 or control siRNA and optionally also PT into 
nanoparticles. 
 
Figure 19: Schematic illustration of T-shaped oligomer 1198. 
Abbreviations of individual units indicate: K: lysine, C: cysteine, Y: tyrosine, 
Stp: succinoyl-tetraethylene-pentamine, OleA: oleic acid, N3: azide function. 
 
When tumors reached a size of 200 to 250 mm³, treatments via tail vein 
injection were started individually. Mice were injected with 
GE11-PEG-modified 1198 with siEG5 respectively siCtrl and with or without 
PT. Free PT and HBG served as controls.  
All tumors of HBG and siEG5 respectively siCtrl group without 
co-formulation with PT exhibited fast tumor progression after the start of 
injections and neither of the treatments could inhibit tumor growth. This 
ultimately led to an overall survival until day 5 (siEG5), respectively 
day 6 (siCtrl) or day 7 (HBG) after treatment start. In all PT-containing 
groups, however, tumor growth ceased after 3 injections and tumors began 
to slowly shrink during the treatment period. Various tumors even fell below 
the measurable size (1 × PT, 1 × siCtrl + PT, 2 × siEG5 + PT). After the end 
of treatments, tumor growth in all groups eventually proceeded (Figure 20), 
resulting in an overall survival until day 22 (PT), respectively day 23 (siCtrl 
+ PT) and day 26 (siEG5 + PT). Yet, not all tumors of each group had 
resumed growing by then, which explains the lack of statistical significance. 
The last animal that had to be sacrificed due to its tumor burden survived 
until day 40 (PT), 46 (siCtrl + PT) and 58 (siEG5 + PT), respectively 
(Figure 21).  
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Figure 20: Tumor growth inhibition by systemic administration of HBG, 
free PT, siEG5 or siCtrl containing GE11-PEG 1198 formulations with or 
without co-formulation with PT in HUH7 tumor bearing mice. Day 0 
represents the day of individual treatment start, treatments were repeated 
thrice weekly for up to 7 times (mean + S.E.M.; n=6). 
 
Figure 21: Kaplan Meier survival analysis of HUH7 tumor bearing mice 
treated intravenously with HBG, free PT, siEG5 or siCtrl containing 
GE11-PEG 1198 formulations with or without co-formulation with PT (n=6). 
 
 
To monitor animal well-being and detect any injection-related adverse 
effects, weight was monitored daily. Figure 22 depicts the weight 
development starting on day -1, one day prior to treatment start and ending 
with euthanasia. The even curve progression of all groups does not indicate 
any side effects during the treatment period. 
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Figure 22: Weight development over time of HUH7 tumor bearing mice 
treated intravenously with HBG, free PT, siEG5 or siCtrl containing 
1198 formulations with or without co-formulation with PT. Day 0 represents 
the day of individual treatment start, treatments were repeated thrice weekly 
for up to 7 times (mean + S.E.M.; n=6). 
 
All in all, the GE11-PEG formulation containing siEG5 in combination with 
PT led to an advantage in tumor growth inhibition and prolonged survival as 
compared to all other treatment groups. 
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2. Combinatorial treatment of PT and MTX 
In this chapter, a potentially beneficial combination effect of the natural 
compound pretubulysin (PT), a potent tubulin-binding antitumoral drug, and 
the well-established antimetabolite methotrexate (MTX) was evaluated in 
several approaches. First, a conjugate of both components was injected 
intratumorally into KB tumor bearing mice. Secondly, a combination of the 
free drugs was analyzed in a treatment experiment with systemic 
administration in various tumor models. Finally, both drugs were 
encapsulated and co-delivered in another treatment experiment with 
intravenous injections in L1210 tumor bearing mice. In vitro assays 
concerning PT+MTX in L1210 and KB tumors were performed by Ines 
Truebenbach (PhD student at Pharmaceutical Biotechnology, LMU). Miriam 
Höhn (chemical technician at Pharmaceutical Biotechnology, LMU) 
contributed to acquiring CLSM images. Johannes Schmaus (veterinary MD 
student at Pharmaceutical Biotechnology, LMU) assisted during the 
454 PT+MTX treatment experiment. 
2.1. Intratumoral treatment with E4-MTX-H-PT conjugate 
The covalent coupling of compounds enables their simultaneous delivery 
and, in case that targeting ligands are involved, facilitates 
receptor-mediated uptake. 
Via solid-phase supported synthesis, a conjugate of E4-MTX oligoamide 
(ID 951, Figure 23) with a thiol-reactive PT derivative was synthesized. The 
oligomer exhibits a 4-arm topology, as this structure achieved the best 
results in vitro in the FR-overexpressing KB cell line as compared to linear 
or 2-arm oligomers. In order to determine if this effect also accounted for 
the situation in vivo, mice were inoculated with subcutaneous KB tumors. 
Intratumoral treatments with the aforementioned co-formulation, 
free PT-COOH or the 4-arm E4-MTX oligomer alone started on day 2 and 
were repeated 5 times, while control animals remained untreated 
(Figure 24). 
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Figure 23: Schematic illustration of 4-arm E4-MTX (ID 951). 
Abbreviations of individual units indicate: C: cysteine, K: lysine, E4: four 
glutamic acids; STOTDA: short ethylene glycol linker N-succinyl-4,7,10-
trioxa-1,13-tridecanediamine; PEG12: polyethylene glycol unit containing 12 
ethylene oxide units; MTX: methotrexate ligands. 
 
 
Figure 24: Mechanism of action of E4-MTX-H-PT conjugate. Mice are 
injected intratumorally with E4-MTX-H-PT conjugate. Particles cross the 
extracellular matrix and, mediated by the targeting ligand MTX, get 
internalized into their target cell by FR and RFC. Once inside the cytosol, 
PT inhibits microtubule, while MTX competitively inhibits DHFR.  
 
 
The 4-arm E4-MTX oligomer alone did not mediate any antitumoral effect 
as compared to the untreated control group. Both PT formulations inhibited 
tumor growth and resulted in noticeably reduced tumor volumes in 
comparison to the other groups during treatment phase. However, after the 
last injection tumor growth proceeded in both groups (Figure 25). The first 
animal of E4-MTX group had to be sacrificed on day 22, while all untreated 
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and PT-treated mice survived until day 23 and injections with 
E4-MTX-H-PT conjugate led to an overall survival until day 27. During the 
whole experiment the body weight was monitored. The lack of injection-
related weight loss in combination with a good general condition indicates 
that intratumoral injections and the associated narcosis were tolerated well 
by the animals (Figure 26). 
In conclusion, we demonstrated a marked tumor growth retarding effect of 
PT on KB cells upon intratumoral injections. In addition, we revealed that 
the E4-MTX-H-PT conjugate mediated comparable antitumoral effects and 
resulted in the longest survival of all animals. 
 
Figure 25: Tumor growth over time starting on day 0 with KB tumor cell 
inoculation and ending with euthanasia. Intratumoral injections are indicated 
by black arrows. Represented is the mean + S.E.M. of 8 mice per group. 
Graph is adapted from Truebenbach et al. [148]. 
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Figure 26: Weight development over time, starting on day 0 with KB 
tumor cell inoculation and ending with euthanasia. Intratumoral injections 
are indicated by black arrows. Represented is the mean + S.E.M. of 8 mice 
per group. Graph is adapted from Truebenbach et al. [148]. 
 
 
2.2. Combined antitumoral effects of PT and MTX after systemic 
application 
Research in our lab went on to testing free PT and MTX separately or in 
combination (PT+MTX) for their antitumoral activity in L1210 leukemia cells 
and KB cervix carcinoma cells in vitro in various assays. Cytotoxicity (MTT) 
assays revealed strong antitumoral effects of PT and MTX on L1210 cells, 
while the PT+MTX combination even yielded in a synergistic effect. In 
cultured KB cells, however, MTX mediated only minor cell killing. Clear 
antitumoral effects were displayed by PT alone, but could not be enhanced 
by combination with MTX. Cell cycle analysis confirmed the previously 
described MTX triggered G1/S-arrest [158, 159] and PT-induced 
G2/M-arrest in both cell lines [140, 144, 160]. Yet, PT+MTX induced a 
G2/M-arrest which exceeded the G2/M-arrest caused by PT alone. In an 
apoptosis assay, no advantage of PT+MTX over the single drugs could be 
accomplished. Subsequently, confocal laser scanning microscopy (CLSM) 
was performed and images demonstrated alterations of cell morphology and 
actin cytoskeleton induced by MTX treatment, especially of KB cells. PT, in 
turn, caused nuclear fragmentation and microtubule disruption and 
treatment with PT+MTX resulted in a combination of the effects of the single 
drugs. 
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Based on these encouraging results, the next step was to test the efficacy 
of the combinatorial treatment in an in vivo mouse model. Therefore, the 
abovementioned cell lines L1210 and KB were chosen and an additional 
experiment in HUH7 hepatocellular carcinoma was compiled. 
To determine an optimum dose of PT, we performed an internal dose finding 
experiment based on doses used in successful in vivo experiments 
published by other groups [140, 144, 145]. KB tumor bearing animals were 
injected every second day with 0.1, 0.2 or 0.4 mg/kg of PT. However, we 
did not find any advantageous tumor growth inhibition after these multiple 
intravenous injections. Subsequently, two single animals were injected with 
1.5 mg/kg respectively 3 mg/kg PT, the former dose was well accepted, the 
mouse injected with the latter dose, however, showed side effects in the 
form of severe weight loss after the 5th treatment and had to be sacrificed 
for reasons of animal welfare. Therefore, we chose a dose of 2 mg/kg for 
the following treatment experiments. 
 
2.2.1. Effect of PT+MTX combination therapy on L1210 tumor 
growth 
First, PT+MTX combination treatment was evaluated in the L1210 tumor 
model, since in vitro cytotoxicity (MTT) data revealed synergistic effects of 
the combination. 
Intravenous treatments with HBG, PT (2 mg/kg), MTX (5 mg/kg) or the 
combination of both (PT+MTX) were started on day 3 after tumor cell 
inoculation and were repeated up to 7 times. Animals were sacrificed when 
termination criteria were reached, respectively on day 13 and 14 in case of 
MTX treated mice. Animals of this group were euthanized together with all 
other mice of MTX dose finding experiment (see III.2.2.1.1.) on day 14. Yet, 
one animal reached the critical tumor size one day earlier and had to be 
sacrificed ahead of schedule. 
Tumors started to grow around day 9 in HBG and MTX group and with a 
delay of 2 days, also in PT group. In the group treated with PT+MTX, tumor 
growth could largely be inhibited until day 17, when tumor volume also 
started to increase (Figure 27A). In a comparison of tumor sizes on day 13 
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(Figure 27B), tumors of PT+MTX group were significantly smaller than 
tumors of all other groups (PT+MTX vs. PT: 0.0132). 
Animals of this group also survived significantly longer than animals of HBG 
group (p = 0.0062) and mean survival was 5 days longer than in PT treated 
animals. Furthermore, weight development was recorded for the duration of 
the experiment to monitor animal well-being, especially during injections. 
Although mice of PT+MTX group gained less weight during the first days, 
all groups showed a constant weight development throughout the 
experiment (Figure 28).  
Figure 27: Tumor growth inhibition of subcutaneous L1210 tumors 
treated intravenously with HBG, MTX, PT or PT+MTX. A) Tumor growth of 
L1210 tumors throughout the experiment. Animals were treated 
intravenously with 250 µL of HBG, MTX, PT or PT+MTX combination 
(mean + S.E.M.; n=4; *p = 0.0293). B) Comparison of tumor sizes on day 13 
after tumor cell inoculation (mean + S.E.M.; n=4; *p = 0.0132,  **p < 0.01). 
  
 
 
Figure 28: Weight development throughout PT+MTX combination 
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therapy experiment in L1210 tumor bearing animals, starting on day 0 with 
tumor cell inoculation. Represented is the mean + S.E.M. of 4 mice per 
group. 
 
 
2.2.1.1. Dose finding of MTX 
The dose of MTX used in the animal experiments was based on efficacy in 
cell culture experiments and is lower than used in some other work. 
Burger et al. described 100 mg /kg as the maximum tolerated dose of MTX 
for NMRI nude mice [161]. Therefore, a new dose finding experiment was 
conducted. 
The experiment was performed in two parts (low dose and high dose MTX) 
to evaluate the best working dose for tumor growth inhibition in vivo. 
L1210 cells were inoculated and injections of MTX respectively HBG were 
carried out three times per week. Neither in the first part of the experiment 
comparing lower doses of 2.5, 5, 7, 10 and 20 mg/kg, nor in the second part 
comparing 40, 80 and 100 mg/kg we could observe any significant 
antitumoral effect of MTX as compared to HBG treated animals 
(Figure 29A+B). However, especially in the group treated with the highest 
dose of 100 mg/kg, side effects in the form of severe weight loss and notably 
affected well-being occurred (Figure 29C). Consequently, 2 out of 4 animals 
had to be sacrificed before reaching the critical tumor volume for reasons of 
animal welfare. 
In sum, no significant tumor growth inhibition could be shown for any of the 
tested doses. Yet, tumor growth inhibition was the most pronounced in MTX 
100 mg/kg group. Also, given the incidents which occurred in this group, the 
use of higher doses is inconvenient. 
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Figure 29: MTX dose finding experiments. A) L1210 tumor growth and 
comparison of tumor sizes on day 13 of animals treated with doses of 2.5, 
5, 7, 10 and 20 mg/kg of MTX. B) Tumor growth and comparison of tumor 
sizes on day 13 of animals treated with 40, 80 and 100 mg/kg of MTX. 
C) Weight development of animals in both experimental parts. Intravenous 
injections are indicated by black arrows (mean + S.E.M.; n=4). 
 
To evaluate a potential formation of chemoresistance, which could be 
acquired during multiple treatments, one tumor of 5 mg/kg MTX group and 
of 80 mg/kg MTX group, respectively, was processed for an MTT assay of 
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in vivo passaged L1210 cells. Cell viability was analyzed after 72 h of MTX 
treatment and revealed no resistance of L1210 cells to MTX, even at a high 
dose of 80 mg/kg. 
 
2.2.2. Effect of PT+MTX combination therapy on KB tumor growth 
Subsequently, the combination therapy was evaluated in a xenograft mouse 
model. Treatments with PT, MTX, PT+MTX or HBG were started 
individually, when KB tumors reached 200-250 mm³ and repeated 3 times 
per week. After treatment start, tumor growth in the HBG injected group 
proceeded rapidly, so the first animal had to be sacrificed after 11 days. 
Tumor growth in MTX treated animals was slightly slowed down after one 
week of treatments and the first animal was sacrificed after 12 days. 
Notably, tumor growth in both PT containing groups was retarded from the 
first injection on and could be further inhibited in the PT+MTX combination 
group (Figure 30A). While the first animal of PT group was sacrificed on 
day 15 after treatment start, PT+MTX combination led to an overall survival 
until day 23. Figure 30B depicts a comparison of tumor sizes on day 11, 
indicating that tumors of PT+MTX group are significantly smaller than in 
HBG and MTX treated mice (PT+MTX vs. HBG: p = 0.0052; PT+MTX vs. 
MTX: p = 0.0066). Also, tumors of PT group are clearly larger in size 
compared to PT+MTX group. Unfortunately, one of the tumors in the PT 
treated group showed a slow initial tumor growth, resulting in a high 
standard error of the mean (S.E.M.). Differences in tumor growth and 
volume to the PT+MTX group are therefore not statistically significant. 
Moreover, the animals’ weight was monitored regularly, ensuring a 
continuous monitoring of animal welfare during the experiment. The 
unobtrusive weight development of all groups indicates that treatments were 
well tolerated by the animals (Figure 31).  
 
III. Results     57 
Figure 30: Tumor growth inhibition of subcutaneous KB tumors treated 
intravenously with HBG, MTX, PT or PT+MTX. A) Tumor volume of 
subcutaneous KB tumors. Intravenous treatments were started individually 
when tumors reached 200-250 mm³ and were repeated 3 times per week 
with a maximum of 8 injections. Day -1 represents one day prior to treatment 
start (mean + S.E.M.; n=4). B) Comparison of tumor sizes on day 11 after 
treatment start (mean + S.E.M.; n=4; *p < 0.05, **p < 0.01, ns: not 
significant). 
 
 
Figure 31: Weight development throughout PT+MTX combination 
therapy experiment in KB tumor bearing animals, starting on day -1, one 
day prior to treatment start, and ending with euthanasia. Intravenous 
treatments with HBG, MTX, PT or PT+MTX were performed thrice weekly 
with a maximum of 8 injections. Represented is the mean + S.E.M. of 4 mice 
per group. 
 
2.2.3. Effect of PT+MTX combination therapy on HUH7 tumor growth 
As third tumor model, hepatocellular carcinoma HUH7 was chosen for a 
repetition of PT+MTX combination experiment. This cell line was selected, 
as its sensitivity to treatments with PT has previously been reported [144]. 
After sufficient tumor growth (when tumors reached 200-250 mm³), 
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intravenous injections with HBG, PT, MTX or the combination of both 
(PT+MTX) were started. Animals were sacrificed after reaching the 
determined termination criteria and Kaplan Meier survival analysis was 
compiled. 
Similar to treatment of KB tumors, MTX alone showed only minor effect on 
HUH7 tumor growth. Like in HBG injected mice, the first animal of MTX 
group had to be sacrificed on day 7 after treatment start due to its tumor 
burden. In contrast, both PT containing groups exhibited significantly 
inhibited tumor growth. Tumors ceased to grow after only 2 treatments and 
even started to shrink during the next injections. Only after the end of 
treatments, tumors of PT group resumed growth, while in PT+MTX group, 
the inhibition of tumor growth lasted around 3 days longer (Figure 32A). 
This led to an overall survival of all animals for 22 days in case of PT vs. 
25 days in case of PT+MTX. Yet, in both groups not all animals showed 
resumed tumor growth when the first animal was sacrificed, respectively. In 
PT group, 2 out of 4 animals exhibited small tumors (< 300 mm³) on day 22, 
whereas in PT+MTX group tumor sizes of even 3 mice were below 300 mm³ 
on day 25. Obviously, this had a massive impact on statistics leading to a 
high standard error of the mean (S.E.M.) and no statistical significance was 
reached between both groups (Figure 32B).  
Figure 32: Tumor growth inhibition of subcutaneous HUH7 tumors 
treated intravenously with HBG, MTX, PT or PT+MTX. A) Tumor growth of 
HUH7 tumors. Treatments were started individually when tumors reached 
200-250 mm³ and were repeated 3 times per week with a maximum of 
8 injections. Day -1 represents one day prior to treatment start 
(mean + S.E.M.; n=4). B) Comparison of tumor sizes of PT and PT+MTX 
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group on day 20 after treatment start (mean + S.E.M.; n=4; ns: not 
significant). 
 
Figure 33 depicts an analysis of the mouse survival, which clearly could be 
prolonged by treatment with PT, while combination with MTX resulted in 
further extended survival.  
 
Figure 33: Survival of HUH7 tumor bearing mice. A) Kaplan Meier 
survival analysis of HBG, MTX, PT or PT+MTX treated groups (n=4 mice 
per group). B) Mean survival of indicated groups (mean + S.E.M.; n=4; 
**p < 0.01, ns = not significant) 
 
Animals were weighed daily and a weight curve was compiled to monitor 
the mice’s well-being. Figure 34 demonstrates a very constant weight 
development throughout treatments in all groups and a steady increase of 
weight after the end of treatments in both PT containing groups. 
 
 
Figure 34: Weight development throughout PT+MTX combination 
therapy experiment in HUH7 tumor bearing animals, starting on day -1, 
one day prior to treatment start, and ending with euthanasia. Intravenous 
treatments were performed thrice weekly with a maximum of 8 injections. 
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Represented is the mean + S.E.M. of 4 mice per group. 
 
 
Summing up the results of all experiments, we showed the advantage of 
PT+MTX combination over the effect of the single drugs in all three cell lines 
while no injection-related adverse effects were observed. 
 
 
2.3. Oligomer-based micellar encapsulation of PT+MTX for 
systemic administration 
After the successful treatment experiment with PT+MTX in L1210 tumors 
(see III.2.2.1.), we aimed for a further optimization of systemically 
administered PT+MTX. Micellar encapsulation of PT, MTX and PT+MTX 
with a lipo-oligomer of our library (ID 454, Figure 35) was exploited to 
ensure simultaneous delivery of the drug combination. The T-shaped lipo-
oligomer 454 was chosen for this experiment, since HPLC measurements 
demonstrated very favorable encapsulation efficiency. Additionally, MTT 
assays demonstrated the superiority of encapsulated drug over free drug. 
 
 
Figure 35: Schematic illustration of T-shaped lipo-oligomer 454. 
Abbreviations of individual units indicate: C: cysteine, Y: tyrosine, 
Stp: succinoyl-tetraethylene-pentamine, K: lysine, OleA: oleic acid. 
 
L1210 tumor bearing mice were injected intravenously with plain 454, 
454 PT, 454 MTX, 454 PT+MTX, free PT, free PT+MTX or HBG. An 
additional group with free MTX was waived with regard to the previous 
experiment in which MTX alone did not achieve tumor growth inhibition as 
compared to HBG injected animals. Based on successful previous 
experiments (see III.2.2. and III.1.2.4. [147]), a dose of 2 mg/kg PT was 
chosen. In case of MTX, we had to adjust the previously used dose of 
5 mg/kg to 2.5 mg/kg, as precipitation occurred when formulations were 
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prepared with the higher dose. Treatments in this experiment were repeated 
thrice weekly with a maximum of 8 injections. Animals were sacrificed after 
reaching the determined termination criteria and Kaplan Meier survival 
analysis was compiled. 
The mice’s weight was recorded daily to monitor animal well-being. Two 
animals of 454 MTX group were found dead in their cages one day after the 
first injection. Also, distinct weight loss occurred in several animals of 
454 MTX and 454 PT+MTX group after the first treatment. However, all 
further injections were tolerated well by all mice and weight development 
was unobtrusive throughout the rest of the experiment. During injections, 
animals displayed a rather constant weight, whereas after the end of 
treatments, all surviving mice started to steadily gain weight (Figure 36). 
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Figure 36: Weight development over time. Weight of mice of A) all groups 
and B) HBG, PT+MTX and 454 PT+MTX groups during the experiment, 
starting on day 0 with L1210 tumor cell inoculation and ending with 
euthanasia. Intravenous injections are indicated by black arrows. 
Represented is the mean + S.E.M. of 6 mice per group (454 MTX: n=4). 
 
 
Figure 37 depicts tumor growth of indicated groups. Eight days after tumor 
cell inoculation, tumors of HBG, 454 and 454 MTX groups started to grow 
and subsequently reached their final volume within another 4 to 5 days. All 
PT containing groups succeeded in retarding tumor growth for at least 
14 days. On day 14, tumors of PT+MTX treated animals started growing, 
followed by tumors of mice injected with PT and 454 PT. 454 PT+MTX 
exhibited the strongest tumor growth delay, so tumors did not start to grow 
before day 18, when treatments were nearly terminated. Also, animals of 
this group survived longer than mice of all other groups with the last animal 
being sacrificed on day 38 after tumor cell inoculation. The encapsulation 
with 454 only slightly improved the antitumoral effect of PT, whereas 
PT+MTX without 454 demonstrated a poorer performance than all other PT-
containing groups. However, this ultimately resulted in a significantly longer 
survival of 454 PT+MTX treated mice as compared to animals of PT+MTX 
group (log rank test of Kaplan Meier curve PT+MTX vs. 
454 PT+MTX: 0.0131) (Figure 38).  
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Figure 37: Tumor growth over time in L1210 tumor bearing mice upon 
intravenous treatments with 454, 454 PT, 454 MTX, 454 PT+MTX, PT, 
PT+MTX or HBG. Average tumor volume of A) all groups and B) HBG, 
PT+MTX and 454 PT+MTX groups. Intravenous injections are indicated by 
black arrows. Represented is the mean + S.E.M. of 6 mice per group 
(454 MTX: n=4). 
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Figure 38: Kaplan Meier survival curve of animals treated with 454, 
454 PT, 454 MTX, 454 PT+MTX, PT, PT+MTX or HBG. Survival analysis of 
A) all groups and B) HBG, PT+MTX and 454 PT+MTX treated groups (n=6 
mice per group). Significance of the results was evaluated using log-rank 
test (*p = 0.013). 
 
 
All in all, we demonstrated the enhanced combination effect of PT+MTX 
after micellar encapsulation with clearly improved tumor growth inhibition 
and significantly extended survival of mice. 
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IV. DISCUSSION 
1. Shielded and targeted lipopolyplexes for effective 
siRNA delivery 
Although siRNA emerged as a potent novel tool in the treatment of various 
diseases, the delivery to its target site remains challenging. siRNA by itself 
exhibits very poor pharmacokinetics [17]. Hence, efficient carriers are 
required to prolong circulation times and direct the formulation to its target 
site. Therefore, suitable carrier systems are under investigation. 
Researchers of our group have designed a library of more than 1200 
sequence-defined oligoaminoamides as carriers for nucleic acid delivery. 
These oligomers exhibit significantly reduced cytotoxicity as compared to 
conventional polymers [162, 163], which can be attributed to their smaller 
size and reduced cationic charge. Recently, our group achieved very 
promising results in nucleic acid delivery using these polymeric carriers 
[156, 162, 163]. However, success rates were often hampered by the 
repeated occurrence of stability issues, rapid renal clearance and reduced 
efficiency upon systemic administration. To overcome these drawbacks, 
polymers were modified, resulting in further optimized carrier systems with 
advantageous properties. For the following experiments, various oligomers 
of our library were chosen for efficient siRNA delivery to subcutaneous 
tumors upon systemic administration. Also, we explored PSar as novel 
shielding agent in comparison to the well-established shielding agent PEG. 
Moreover, we exploited active targeting for the effective direction of 
nanoparticles to their site of action. 
1.1. PEG and PSar as shielding agents 
Shielding of nanoparticles prevents rapid renal clearance, unwanted 
interactions with blood components or other nanoparticles and thereby 
enhances their circulation time, which ultimately enables the formulation to 
reach therapeutic levels at its target site [50-53]. PEG has been used for 
surface shielding for almost 30 years [50]. However, researchers reported 
immune responses associated with repeated PEG treatments, potentially 
hampering its clinical usability [55-62]. 
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In this thesis, the shielding capacity of PSar was evaluated in direct 
comparison to PEG in a biodistribution experiment. Encouragingly, PSar 
has already been demonstrated to prolong in vivo circulation times [75, 76] 
and no immunogenicity has been reported until now [77].  
In the current approach, an azide functionality was introduced into T-shaped 
oligomers of our library [49]. Azide groups enable copper-free click reactions 
with cyclooctyne derivates and by that an alternative method for the 
introduction of functional domains to the lipoplex [151, 152]. In former work, 
functional groups of oligomers, for example thiols, were exploited for this 
purpose [157, 164-166]. Although promising results regarding gene 
silencing and biophysical properties were achieved in vitro, in vivo delivery 
of siRNA was frequently compromised by stability issues. Bio-orthogonal 
click chemistry offers some valuable benefits: It proceeds effectively without 
the requirement of a catalyst. Moreover, no potentially harmful side products 
are produced and no cytotoxicity is caused [151-153].  
In the thesis, unshielded lipopolyplexes were compared to lipopolyplexes 
covalently linked to PEG (DBCO-PEG5k) or PSar (DBCO-PSar119-Ac) with 
regard to their distribution upon systemic application. In accordance with 
previous findings of our group [48, 165], the unshielded T-shape 
lipopolyplexes demonstrated a preferred accumulation in the liver [154]. The 
underlying mechanism behind this might be the unspecific interaction of 
unprotected nanoparticles with cell surfaces and serum proteins, which 
consequently affects tissue specificity [167-169].  
As expected, shielding with PEG yielded in significantly prolonged 
circulation time and improved tumor accumulation of our nanoparticles. 
Modification with PSar likewise enhanced biodistribution properties, thus 
surface shielding turned out to be as effective as with PEG. An unexpected 
finding was the strong fluorescence signal in the mice’s paws that lasted 
until 24 h post injection, whereas in most body parts, the signal had largely 
decreased by then. This might possibly be due to anesthesia-induced 
hypotension leading to peripheral vasoconstriction [170-172], hence 
particles of a certain size can get stuck.  
In summary, we provide evidence that shielding with PSar is as effective as 
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with PEG [154]. In future research, carrier systems might require further in 
vivo stabilization to prolong circulation time and enable passive targeting 
[82]. 
1.2. Targeted lipopolyplexes for gene silencing in vivo 
In the previous part, we demonstrated the impact of surface shielding on 
biodistribution upon systemic application. Another important aspect that 
contributes to the successful delivery of nanoparticles is targeting to the site 
of action. Concerning targeting, an active and a passive form can be 
distinguished. Passive targeting occurs due to the EPR effect, a 
combination of suitable particle size, adequate circulation time and leaky 
blood vessels, as well as impaired lymphatic drainage in the tumor area [22, 
39, 82, 173, 174]. Thereby a formulation can effectively be directed to its 
site of action. However, to enable not only the localization, but also the 
actual internalization into the target cell, active targeting might be required. 
Here, receptor-mediated endocytosis is facilitated by the modification of 
nanoparticles with specific ligands. These mediate a high selectivity in 
cellular binding caused by their ability to target specific receptors 
overexpressed by many solid tumors [53, 155]. In the following experiments, 
we mainly focused on the FR. FR is overexpressed by many carcinoma cell 
lines [87, 94], which require high amounts of folate for the synthesis of 
nucleic acids due to their increased division rate. 
An azido function was incorporated into a T-shape oligomer with promising 
carrier properties [49] to enable the introduction of functional domains using 
bio-orthogonal click chemistry. Subsequently, the obtained core polymer 
1106 was modified with DBCO-PEG for surface shielding. Furthermore, the 
targeting ligand folate was incorporated into this domain, yielding in particles 
with optimized properties in terms of successful siRNA delivery. To analyze 
different variants of this carrier system, both mono- and (double-click) 
bis-DBCO, as well as different PEG lengths and modification with folate as 
targeting ligand, were investigated [147]. 
First, biodistribution of our formulations was evaluated upon systemic 
administration. Similar to the previous part, unshielded polyplexes mainly 
accumulated in the liver tissue, which is a common finding for unshielded 
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T-shape oligomers [48, 165]. No improvement of circulation time or tumor 
accumulation was achieved by incorporating mono-DBCO with either length 
of PEG. Yet, modification with bis-DBCO clearly prolonged blood circulation 
[147]. This might be explained by an enhanced stability mediated by the 
crosslinking with a second lipo-oligomer. Surprisingly, the introduction of the 
targeting ligand FolA led to a broader distribution with prolonged blood 
circulation. Based on an internal experiment, in which we found L1210 
tumors to metastasize at an early stage (unpublished data), we assumed 
that the enhanced circulation of FolA-targeted formulations is attributed to 
tumor cells that have spread from the primary tumor to distant body parts. 
As anticipated, when administered into tumor-free mice, the best-
performing formulation DBCO2-ss2-PEG24 FolA displayed weaker 
biodistribution properties than in L1210 tumor bearing mice [147].  
We further investigated whether the replacement of cholanic acid (CholA) 
by oleic acid (OleA) in the lipo-oligomer core resulted in beneficial 
biodistribution properties since transfection efficiency in vitro was similar for 
both oligomers (unpublished data). Fatty acids are incorporated for their 
hydrophobic character which enhances polyplex stability. In former in vivo 
experiments of our group, OleA was successfully used with FolA-targeted 
formulations [156, 157]. Yet, in the current approach the OleA analog 1169 
did not exhibit any advantageous effect as compared to 1106 [147]. Also in 
different previous work, the saturated C24 bile acid derivative CholA was 
chosen over the unsaturated C18 fatty acid OleA, as it exhibits higher 
stability both during synthesis and storage [49]. 
Moreover, the same formulation was evaluated in terms of gene silencing 
efficiency using siRNA against mRNA of the EG5 gene. EG5, also referred 
to as eglin 5 or kinesin spindle protein (KSP), is a member of the kinesin 
family. It is actively involved in the assembly of the spindle apparatus during 
cell division [175]. Therefore, it represents a powerful target for anti-cancer 
therapeutics. Through the inhibition of protein translation of EG5, mitosis is 
hampered, cells accumulate in the G2/M phase and ultimately die [176, 
177]. By directing 1106 DBCO2-ss2-PEG24 FolA towards EG5, we reached 
~60% of gene silencing, whereas the untargeted analog showed negligible 
effects on EG5 expression [147]. This demonstrates the pronounced 
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advantage of folate targeting. Also, unspecific effects of the polyplexes 
themselves on EG5 could be excluded, since only minor decrease of the 
mRNA level was achieved by the targeted siCtrl formulation. The 
experiment was repeated with the OleA containing analog 1169. In this 
case, the FolA targeted siEG5 formulation only led to ~40% of gene 
silencing. Hereby, we could confirm the superiority of CholA containing 1106 
over 1169, which was already observed during biodistribution experiments. 
While biodistribution only provides information about in vivo circulation and 
tumor accumulation, the significant downregulation of EG5 expression by 
1106 formulation proves the successful internalization of the polyplexes and 
cytosolic siRNA release [147]. 
Based on these encouraging findings, a treatment experiment was 
performed to evaluate the antitumoral potency of 1106 DBCO2-ss2-
PEG24 FolA siEG5 in combination with the potent microtubule inhibitor 
pretubulysin (PT). PT has emerged as promising candidate of the group of 
microtubule-targeting agents. As precursor of the tubulysins, which have 
recently been evaluated in several clinical trials [178], it is almost as 
effective but in the same time easier to synthesize due to its simplified 
chemical structure [140, 141, 144]. PT was chosen as it exhibits very 
favorable antitumoral effects in vivo [140, 144, 145, 148] and promotes cell 
accumulation in the G2/M phase, like siEG5 [137]. However, this natural 
compound is directed at a different mechanism, namely the vinca domain of 
β-tubulin. After binding to its target site, it inhibits tubulin polymerization, 
which consequently leads to an inhibition of mitosis and cell death [142, 
143].  
Encouragingly, intravenous treatments of L1210 tumor bearing mice with 
the siEG5 + PT containing formulation resulted in significant tumor growth 
inhibition and extended survival [147]. While tissue specificity and enhanced 
circulation time are provided by the optimized carrier system with FolA 
targeting and PEG shielding, both siEG5 and PT interfere with the mitotic 
spindle apparatus but in a different manner. This provides a coherent 
explanation for the encouraging effect of this combination. 
Given the successful treatment of FR-overexpressing L1210 tumors [147], 
the experimental setup was taken up in a new in vivo experiment aiming at 
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a different target. Therefore, the human hepatocellular carcinoma cell line 
HUH7 was chosen, since these tumors –like many other solid tumors, are 
known to overexpress epidermal growth factor receptor (EGFR) [111]. 
EGFR, in turn, can be targeted by the targeting ligand GE11, a short artificial 
peptide which - in contrast to the natural ligand EGF - lacks mitogenic 
activity [114]. Hence, GE11 was included in our formulation. Analogous to 
the previous experiment with L1210 tumors, it further contained siEG5 and 
PT.  
Notably, intravenous treatments with this formulation achieved remarkable 
tumor growth inhibition. Tumor progression could be stopped during 
treatments with all PT containing formulations, leading to major differences 
in tumor sizes between PT containing and PT free groups, but less 
pronounced differences within these groups, respectively. This indicates a 
predominant PT effect. The great sensitivity of HUH7 tumors to treatment 
with PT has previously been demonstrated by Rath et al. [144]. Moreover, 
the authors could show the significantly reduced vessel density of HUH7 
tumors upon PT treatment, confirming the anti-angiogenic effect that was 
described earlier by Kaur et al. for tubulysin A [179]. Thereupon, a reduced 
vascularization deprives the tissue of nutrients and oxygen, urgently needed 
by the growing tumor [180, 181]. After the end of treatments however, 
tumors of all groups eventually resumed progression. Yet, animals treated 
with PT in combination with siEG5 displayed strongest tumor growth 
inhibition and longest survival of all groups. Presumably, this can be 
attributed to the additional mitosis inhibition mediated by siEG5. Lee et al. 
reported the recurrence-free survival of 50% of mice treated intratumorally 
with a combination of siEG5 and MTX-conjugated polyplexes, while the 
same formulation without siEG5 did not inhibit KB tumor growth [182]. Given 
the predominant PT effect, we need to conclude that the combination effect 
of siEG5 and PT in the current study was not as pronounced as in the 
previous experiment with FolA targeting. 
Taking together the promising results of both treatment experiments, the 
combination of eglin 5 siRNA with PT, both aiming at the same intracellular 
target but affecting it in different manners, represents a promising approach 
in the treatment of various forms of cancer. However, further experiments 
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should be conducted, investigating the effect of this combination in more 
cell lines and with further improved oligomeric carrier systems for effective 
delivery and improved circulation times. Moreover, an interesting aspect 
would be the histologic evaluation of tumor tissue during treatments for a 
precise evaluation of the PT and siEG5 combination effect. 
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2. Combinatorial treatment of PT and MTX 
The use of drug combinations becomes increasingly important as standard 
therapy setting for the treatment of cancer. While monotherapy approaches 
often fail to control this medical condition successfully [122, 123, 183, 184], 
combination therapy settings represent a promising strategy as they can 
address the disease from different angles [185-187]. According to 
Zimmermann et al., multi-target therapeutics can be divided into three 
groups: (i) two components aiming at two separate targets, (ii) one 
component enabling the second to attack its target or (iii) two components 
binding to separate sites of one target [188]. 
In the following studies, we aimed for a possibly beneficial combinatorial 
effect of PT and the well-established chemotherapeutic drug methotrexate 
(MTX).  
 
2.1. Intratumoral treatment with E4-MTX-H-PT conjugate 
In the first attempt, MTX was exploited, on the one hand, for its inhibitory 
effect on DHFR, an enzyme that transforms folic acid to dihydrofolic acid 
and finally tetrahydrofolic acid which is required for the de novo synthesis of 
DNA and RNA [109, 110]. On the other hand, we also took advantage of its 
function as targeting ligand, enabling a formulation to precisely address 
cells overexpressing the folate receptor [131, 189], which accounts for many 
carcinoma cell lines [87, 94].  
In this experiment, co-delivery of PT and MTX was achieved by the covalent 
attachment of thiol-reactive PT derivatives to cysteine residues of MTX-
oligoamides [148]. By administering both compounds as a conjugate, we 
aimed at improved cell internalization through receptor-specific uptake, as 
well as a combination effect of PT and MTX. 
For the in vivo treatment study, a 4-arm E4-MTX oligoamide was chosen. 
E4-MTX refers to the bioactive (tetraglutamylated) form of MTX, which 
usually is generated by the folyl-polyglutamate synthase after internalization 
into the target cell [126, 190]. During treatments of mice bearing 
subcutaneous FR-overexpressing KB tumors, E4-MTX alone was found to 
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have no tumor growth retarding effect as compared to the untreated controls 
[148], which is in accordance with previous findings of our group [182]. The 
antitumoral effect mediated by the conjugate was similar to native 
PT-COOH. However, as PT in the conjugate was used in the form of its 
hydrazide derivative, which in vitro was inferior to native PT-COOH, our 
finding can be regarded as a valuable result [148]. Moreover, we could show 
for the first time the antitumoral effect of PT in the KB tumor model [148].  
Yet, with regard to clinical relevance, local application of drugs in most 
cases is inconvenient or insufficient. Therefore, future experiments should 
focus on the systemic delivery of these conjugates. For this purpose, renal 
clearance has to be overcome and circulation time should be prolonged to 
reach therapeutic levels in the tumor tissue.  
 
2.2. Combined antitumoral effects of PT and MTX 
Subsequently, we evaluated the potential combination effect of free PT and 
MTX after systemic administration in vivo.  
We first chose the L1210 murine leukemia tumor model, since in vitro 
cytotoxicity studies demonstrated that PT and MTX acted synergistically on 
L1210 cells, exceeding the effect of both compounds alone. In contrast to 
the in vitro cytotoxicity (MTT) assay, MTX did not achieve an inhibition of 
L1210 tumor growth in vivo. However, this finding is supported by previous 
studies in which free MTX could neither cause tumor growth inhibition [148, 
182]. PT on the other hand, exhibited a strong antitumoral effect on L1210 
tumors during multiple intravenous injections which is in accordance with 
previous experiments in MDA-MB-231 [140], HUH7 [144] and L1210 tumors 
[147]. Encouragingly, this favorable effect could be further enhanced by 
co-administering PT with MTX, resulting in a significantly retarded tumor 
growth in the combination group. 
Notably, the doses of PT and MTX used in these animal experiments were 
chosen based on in vitro experiments and an internal dose-finding 
experiment with PT. Subsequently, a dose-finding experiment was 
performed to evaluate the best working dose of MTX. Considering the 
comparison of tumor growth curves after multiple intravenous injections with 
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different doses of MTX, it becomes obvious that the dosage of MTX used in 
the animal experiments was inferior to higher doses of MTX. Burger et al. 
described 100 mg/kg as the maximum tolerated dose (MTD) for NMRI nude 
mice [161]. This could be confirmed by our group since 2 out of 4 animals 
suffered from severe side effects and consequently had to be sacrificed for 
reasons of animal welfare. However, even after multiple injections with the 
highest doses of 80 mg/kg and 100 mg/kg, we did not achieve a significant 
tumor growth inhibition. A reason for the lack of an MTX effect in vivo could 
be an acquired resistance that formed during the in vivo experiment due to 
multiple treatments. In vivo passaged tumors were investigated towards 
such a resistance in cell culture. However, they were still sensitive to MTX. 
Yet, the differences in tumor growth inhibition indicate that the combination 
effect achieved with the suboptimal dose of 5 mg/kg MTX is even more 
remarkable and could be further enhanced by adjusting the dose of MTX. 
Subsequently, the experiment was repeated in the KB human cervix 
carcinoma model and in the HUH7 hepatocellular carcinoma. In both tumor 
models, PT had already previously demonstrated advantageous antitumoral 
effects [144, 148]. In our current study, we confirmed antitumoral activity of 
2 mg/kg PT upon multiple intravenous injections. MTX slightly but not 
significantly inhibited KB tumor growth after multiple 5 mg/kg i.v. injections. 
This is consistent with the known in vitro partial chemoresistance of KB cells 
to MTX [190] and our previous in vivo studies [148, 182]. Importantly, also 
in this carcinoma model the co-administration of 5 mg/kg MTX resulted in 
an increased antitumoral effect of PT. Thereby, we could show for the first 
time a beneficial effect of PT after systemic administration in the KB tumor 
model. In the HUH7 tumor model, PT mediated significant tumor growth 
inhibition, whereas MTX displayed only minor effects as compared to HBG 
buffer. Yet, the PT+MTX combination resulted in enhanced retardation of 
tumor progression and prolonged survival as compared to PT. We thereby 
confirm the strong antitumoral effect of PT on HUH7 cells, previously 
reported by Rath et al. [144] and demonstrate the advantage of the PT+MTX 
combination approach in a third cell line.  
To conclude, we showed clear antitumoral effects of 2 mg/kg PT in all three 
cell lines in vivo, whereas tumor treatment with 5 mg/kg MTX (or even 
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100 mg/kg in case of L1210 tumors) failed under in vivo conditions. 
Surprisingly, a combination of PT with this low dose of MTX boosted the in 
vivo tumor growth inhibition and prolonged the survival of animals. As 
revealed by CLSM, this effect could be explained by the impairment of the 
actin cytoskeleton of the cell by MTX, which was previously reported by 
Otrocka et al. [191] and Mazur et al. [192]. An unimpaired cytoskeleton is 
required for the formation of actin stress fibers as a cellular survival 
response after treatment with the microtubule inhibitor PT, since several 
studies have shown that microtubule inhibitors likewise influence the actin 
cytoskeleton [193-195]. Hence, treatment with PT+MTX results in an 
enhanced cell killing due to a combined loss in microtubule as well as actin 
cytoskeleton function. 
The promising therapeutic PT+MTX combination effect provides an 
interesting starting point for further biological research and therapeutic 
translation. However, in case of KB and HUH7 tumors, group sizes should 
be adapted to reach statistical significance and increase validity of the 
obtained results. 
 
2.3. Oligomer-based micellar encapsulation of PT+MTX for 
systemic administration 
Encapsulation of PT+MTX in nanoparticular micelles was an approach to 
facilitate simultaneous delivery of the two drugs. Therefore, a suitable 
carrier system was required. Lipo-oligomer 454 was chosen from our library, 
as it exhibited great encapsulation efficiency in vitro. PT, MTX and PT+MTX 
were incorporated into a nano-micellar formulation based on oligomer 454. 
Subsequently, mice bearing L1210 tumors were treated with the 
abovementioned formulations or the respective compounds without 454, 
whereby a group receiving plain MTX was waived considering the lack of 
therapeutic efficiency observed during previous experiments. 
Unexpectedly, distinct weight loss and two cases of death were observed 
after the first injection of 454 MTX and 454 PT+MTX. However, we could 
not identify the cause of these adverse effects, especially since the 
unobtrusive weight development and well-being during all further treatments 
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indicate that formulations were tolerated well by the animals. 
As expected, tumor growth could successfully be inhibited in all 
PT-containing groups. Within these groups, free PT+MTX mediated the 
weakest antitumoral effect, which may be explained by the adjusted dose of 
MTX in comparison to previous experiments. Hence, we hypothesize that 
the aforementioned inhibition of the actin rescue effect by MTX is less 
pronounced and the combined loss in microtubule and actin cytoskeleton 
function mediated by PT+MTX is reduced. In case of PT, nanoparticular 
incorporation did not lead to a superior growth retardation, whereas the 
effect of PT+MTX combination could largely be enhanced in 454 PT+MTX 
group. One advantage of the co-formulation of two drugs within the same 
nanoparticle is their simultaneous delivery, which is not achieved by the 
mere combination of two compounds. Thus, after the injection of PT+MTX, 
both drugs exhibit completely different pharmacokinetics and biodistribution 
occurs in an unspecific manner. Another benefit is the prevention of 
encapsulated drugs from interactions with blood components and by that 
early renal clearance [37, 39]. The likelihood of resistance formation can be 
decreased and previously acquired resistances can even be reversed [196]. 
Moreover, nanoparticle formation of drugs results in improved 
pharmacokinetic behavior and controlled delivery to their site of action [197]. 
In sum, this work showed the successful co-delivery of nanoparticular 
encapsulated PT+MTX in a systemic treatment experiment, leading to 
effective tumor growth retardation and extended survival of so treated mice. 
In future experiments, nanoparticles should be further optimized by 
shielding and targeting domains for enhanced passive and active targeting. 
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V. SUMMARY 
These days, cancer represents one of the leading causes of death 
worldwide. In the near future, the number of newly diagnosed patients will 
continue to rise, since the proportion of elderly people is increasing. Thereby 
also the economic burden associated with the elaborate treatment will 
further increase. Despite intensive research in this area, current treatment 
options only lead to unsatisfying cure rates. Hence, new treatment 
modalities are urgently required. The recent emergence of siRNA as novel 
therapeutic tool holds great promise, with the first FDA approved drug 
Patisiran (OnpattroTM, a PEGylated liposomal siRNA formulation) on the 
medical market. However, siRNA delivery into tumors remains challenging. 
Accordingly, the first part of this thesis aimed at the investigation of 
polymeric nanocarriers for efficient siRNA delivery. Lipopolyplexes 
click-modified with DBCO-containing surface shielding and targeting agents 
were tolerated well upon systemic administration in NMRI-nu/nu mice. In 
Neuro-2a murine neuroblastoma bearing animals, both PEG as the most 
commonly used shielding agent and the novel polysarcosine (PSar) in direct 
comparison demonstrated a comparable in vivo efficiency. In the next part, 
the in vivo delivery of folate (FolA) containing DBCO-PEG polyplexes was 
analyzed in the folate-receptor overexpressing L1210 murine leukemia 
model. A biodistribution study demonstrated the superiority of a formulation 
containing bis-DBCO, PEG24 and FolA with tumor accumulation until 4 h. In 
a gene silencing experiment with intravenous administration, the same 
formulation combined with siRNA against the mitosis-related EG5 gene 
product resulted in significant downregulation of the respective mRNA in the 
subcutaneous L1210 tumor. Subsequently, the formulation was evaluated 
in a systemic treatment experiment in combination with the novel 
microtubule inhibitor pretubulysin (PT). Encouragingly, it accomplished 
significantly inhibited L1210 tumor growth and extended survival. In 
continuation, GE11-containing siEG5 polyplexes were used for treatment 
targeting epidermal growth factor (EGF) receptor-overexpressing human 
HUH7 hepatocellular carcinoma in the xenograft model. A formulation with 
GE11 targeting ligand, siEG5 and PT led to longest survival and 
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pronounced tumor growth inhibition. Yet, the superiority of the combination 
over PT alone did not reach the level of statistical significance due to the 
high antitumoral activity of free PT against HUH7 tumors. 
The use of chemotherapy is frequently impaired by the acquisition of 
resistances, which is commonly associated with monotherapy approaches. 
Currently, the most promising strategy to narrow this risk is combination 
therapy. The second part of this thesis evaluated the combination of PT with 
the antifolate methotrexate (MTX). Firstly, both compounds were covalently 
linked and injected intratumorally into NMRI-nu/nu mice, exploiting MTX on 
the one hand concerning its ability to inhibit DHFR, and on the other hand 
for its ligand qualities associated with the high affinity to the FR. Thereby, a 
retardation of KB tumor growth was achieved similar to treatments with 
native PT. Subsequently, a combination of the free drugs was injected 
intravenously into L1210, KB and HUH7 tumor bearing NMRI-nu/nu mice. 
In all three tumors models, PT+MTX proved to be superior over the effect 
of each drug alone, reaching levels of significance in the L1210 model. 
Finally, PT+MTX was incorporated into a lipo-oligomer nanomicelle to 
provide simultaneous delivery upon systemic administration. 
Encouragingly, L1210 tumor progression could be successfully retarded 
and resulted in significantly prolonged survival as compared to free 
PT+MTX. 
In conclusion, a shielded and targeted carrier nanosystem was validated for 
effective EG5 siRNA delivery, successfully inhibiting tumor growth in 
combination with PT. Moreover, the promising combination effect of PT with 
MTX was described in several tumor models and the enhancement by 
nanoformulation demonstrated. 
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VI. ZUSAMMENFASSUNG 
Antitumorale polymerische siRNA Nanoformulierungen und 
Pretubulysin-basierte Kombinationstherapien 
Krebs stellt in der heutigen Zeit weltweit eine der häufigsten Todesursachen 
dar. Aufgrund des steigenden Anteils an älteren Menschen in unserer 
Bevölkerung, wird die Zahl an neudiagnostizierten Krebspatienten innerhalb 
der nächsten Jahre weiter zunehmen. Damit nimmt auch die wirtschaftliche 
Belastung zu, die mit der aufwendigen Behandlung einhergeht. Trotz 
intensiver Forschung auf diesem Gebiet, können mit den derzeit 
verfügbaren Therapiemöglichkeiten nur unzufriedenstellende 
Heilungsraten erzielt werden. Daher ist die Entwicklung neuer 
Therapieformen von großer Dringlichkeit. Die Verwendung von siRNA als 
therapeutisches Werkzeug stellt einen vielversprechenden neuen Ansatz 
dar, der bereits zur Zulassung eines ersten medizinischen Produktes 
(Patisiran, OnpattroTM, einer PEGylierten liposomalen siRNA Formulierung) 
geführt hat. Die klinische Anwendung von siRNA im Tumorbereich wird 
allerdings derzeit noch beeinträchtigt durch die Schwierigkeiten ihres 
Transports in die Zielzelle. Daher war das Ziel des ersten Teiles dieser 
Dissertation, optimierte polymerische Trägersysteme für den effizienten 
Transport von siRNA zu ihrer Zielzelle zu untersuchen.  
Die vorliegende Arbeit zeigt, dass Lipopolyplexe, die über neuartige 
Click-Chemie mit DBCO-enthaltenden Abschirmungs- und Targeting-
Domänen ausgestattet wurden, nach systemischer Verabreichung in der 
NMRI-nu/nu Maus sehr gut toleriert werden. Sowohl PEG (als das am 
häufigsten zur Oberflächen-Abschirmung eingesetzte Polymer), als auch 
das im direkten Vergleich eingesetzte Polymer Polysarcosine (PSar) 
zeigten eine vorteilhafte Biodistribution im Neuro-2a murinen Neuroblastom 
Mausmodell. Der nächste Teil dieser Arbeit strebte den effizienten 
Transport von DBCO-PEG FolA Polyplexen in die Zielzelle an. Ein 
Bioimaging-Experiment zeigt die Überlegenheit einer Formulierung mit 
bis-DBCO, PEG24 und FolA, die eine Anreicherung im Folatrezeptor-
überexprimierenden L1210 Tumorgewebe bis nach 4 Stunden aufwies. In 
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einem weiteren Versuch wurde die Hemmung der Expression eines 
Genproduktes auf mRNA-Ebene durch die systemische Verabreichung 
einer siRNA in Kombination mit der zuvor beschriebenen Formulierung 
untersucht.  Ziel war in diesem Fall die mRNA des an der Mitose beteiligten 
Gens EG5. Hierbei ergab sich eine signifikante Herabregulierung des 
entsprechenden Genproduktes. Anschließend wurde die selbe 
Formulierung in einem Behandlungsversuch in Kombination mit dem neuen 
Mikrotubuli-Hemmer Pretubulysin (PT) getestet. Erfreulicherweise führte 
eine intravenöse Behandlung mit dieser Kombination zu einem deutlich 
gehemmten L1210 Tumorwachstum und verlängerte das Überleben der 
Gruppe. Darauf aufbauend wurde ein weiterer Behandlungsversuch mit 
GE11-Targeting von EGF Rezeptor-überexprimierenden HUH7 
hepatozellulären Karzinomen durchgeführt. Eine Formulierung mit GE11 
Targeting Ligand, siEG5 und PT führte zum längsten Überleben und am 
deutlichsten gehemmten HUH7 Tumorwachstum. Allerdings sind die 
Ergebnisse aufgrund der starken antitumoralen Wirkung von PT auf HUH7 
Tumore statistisch nicht signifikant.  
Der Einsatz von Chemotherapie wird oft durch die Entwicklung von 
Resistenzen erschwert, welche häufig im Zusammenhang mit 
Monotherapie Ansätzen auftreten. Zurzeit stellt der Einsatz von 
Kombinationstherapie die vielversprechendste Strategie dar, um dieses 
Risiko zu minimieren. Der zweite Teil dieser Dissertation untersucht die 
Kombination von PT mit dem Antifolat Methotrexat (MTX). Zuerst wurden 
beide Wirkstoffe kovalent verbunden und intratumoral in NMRI-nu/nu 
Mäuse injiziert, um gleich zwei Eigenschaften von MTX auszunutzen, 
einerseits seine Fähigkeit, das Enzym DHFR zu hemmen und andererseits 
seine Ligandenqualität, welche durch die hohe Affinität zum Folatrezeptor 
bedingt wird. Hierdurch wurde ein verlangsamtes KB Tumorwachstum 
erreicht, ähnlich wie durch die Behandlung mit freiem PT. Anschließend 
wurde eine Kombination der freien Komponenten in L1210, KB und HUH7 
Tumor tragende Tiere intravenös injiziert. In allen drei Tumormodellen 
zeigte sich ein Vorteil von PT+MTX im Vergleich zur Behandlung mit den 
jeweiligen Wirkstoffen allein, im L1210 Tumormodell erreichte diese 
Überlegenheit sogar statistische Signifikanz. Zuletzt wurde PT+MTX in eine 
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nanopartikuläre Mizelle integriert, um einen gleichzeitigen Transport der 
Wirkstoffe in die Zielzelle zu gewährleisten. Erfreulicherweise konnte das 
L1210 Tumorwachstum während der intravenösen Behandlungen 
erfolgreich gehemmt werden. Der Einbau in eine mizellare Struktur führte 
zu einem signifikant längeren Überleben der Gruppe, verglichen mit Tieren 
der Gruppe freies PT+MTX. 
Zusammenfassend stellt die Dissertation ein polymerisches Trägersystem 
für den Transport von siRNA zur Zielzelle mittels Targeting und Oberfächen-
Abschirmung vor, das in Kombination mit siEG5 und PT erfolgreich das 
Tumorwachstum hemmen konnte. Weiterhin wird ein vielversprechender 
Kombinationseffekt von PT mit MTX in mehreren Tumormodellen 
beschrieben und die Verstärkung dieses Effekts durch Integration der 
Komponenten in eine Nanoformulierung gezeigt. 
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